|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:30677399 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Aifm1 |
apoptosis inducing factor, mitochondria associated 1 |
increases expression |
EXP |
3-methyladenine results in increased expression of AIFM1 protein |
CTD |
PMID:16497721 |
|
NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
ISO |
3-methyladenine results in decreased phosphorylation of AKT1 protein 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:16882451 PMID:32043704 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased expression of APAF1 protein]] |
CTD |
PMID:35149085 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Apod |
apolipoprotein D |
affects localization |
ISO |
3-methyladenine affects the localization of APOD protein |
CTD |
PMID:28182653 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[Hydrogen Peroxide co-treated with 3-methyladenine] results in increased expression of APP protein |
CTD |
PMID:23726866 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Atg4a |
autophagy related 4A, cysteine peptidase |
decreases expression |
ISO |
3-methyladenine results in decreased expression of ATG4A mRNA |
CTD |
PMID:21681844 |
|
NCBI chr X:104,665,345...104,765,271
Ensembl chr X:104,665,345...104,765,268
|
|
G |
Atg4b |
autophagy related 4B, cysteine peptidase |
decreases expression |
ISO |
3-methyladenine results in decreased expression of ATG4B mRNA |
CTD |
PMID:21681844 |
|
NCBI chr 9:94,282,417...94,314,109
Ensembl chr 9:94,282,509...94,314,103
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression decreases expression |
ISO EXP |
3-methyladenine inhibits the reaction [hydroxyethyl methacrylate results in increased expression of ATG5 protein]; ATG5 protein affects the reaction [3-methyladenine results in increased activity of CASP3 protein] 3-methyladenine results in increased expression of ATG5 protein 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of ATG5 mRNA] 3-methyladenine results in decreased expression of ATG5 mRNA; 3-methyladenine results in decreased expression of ATG5 protein 3-methyladenine inhibits the reaction [aristolochic acid I results in increased expression of ATG5 protein]; 3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of ATG5 protein]] |
CTD |
PMID:18818525 PMID:23939141 PMID:28184909 PMID:29128638 PMID:30611790 PMID:32587277 PMID:33462182 More...
|
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atg7 |
autophagy related 7 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [1-nitropyrene results in increased expression of ATG7 mRNA]; 3-methyladenine inhibits the reaction [rottlerin results in increased expression of ATG7 protein]; [Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in increased expression of ATG7 mRNA] 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of ATG7 mRNA] |
CTD |
PMID:22902833 PMID:29078374 PMID:33462182 |
|
NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593
|
|
G |
Atp5pd |
ATP synthase peripheral stalk subunit d |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of ATP5H mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr10:100,657,700...100,662,960
Ensembl chr10:100,657,708...100,663,479
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP ISO |
3-methyladenine inhibits the reaction [citreoviridin results in increased expression of BAX protein]; 3-methyladenine promotes the reaction [4-nonylphenol results in increased expression of BAX protein] 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased expression of BAX protein]; 3-methyladenine inhibits the reaction [Nicotine results in increased expression of BAX protein] |
CTD |
PMID:26804764 PMID:31419397 PMID:32043704 PMID:33010382 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [Arsenic Trioxide results in decreased expression of BCL2]; 3-methyladenine inhibits the reaction [Artesunate results in decreased expression of BCL2 protein]; 3-methyladenine inhibits the reaction [Nicotine results in decreased expression of BCL2 protein]; [3-methyladenine co-treated with Amiodarone] results in decreased expression of BCL2 protein 3-methyladenine inhibits the reaction [Alpha-Amanitin results in decreased expression of BCL2 protein] 3-methyladenine inhibits the reaction [citreoviridin results in decreased expression of BCL2 protein] |
CTD |
PMID:23912912 PMID:25110043 PMID:31419397 PMID:33002460 PMID:33010382 PMID:35175747 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
ISO |
3-methyladenine inhibits the reaction [Fluorouracil results in increased expression of BCL2L1 protein] 3-methyladenine results in increased expression of BCL2L1 mRNA |
CTD |
PMID:19116755 PMID:21681844 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
multiple interactions affects response to substance decreases expression |
EXP ISO |
3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [4-nonylphenol results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Acrylamide results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Ethanol promotes the reaction [Mirtazapine results in increased expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [glycidamide results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Mirtazapine results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [T-2 Toxin results in increased expression of BECN1 mRNA] 3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of BECN1 mRNA]; 3-methyladenine inhibits the reaction [Caffeine results in increased expression of BECN1 protein] BECN1 protein affects the susceptibility to 3-methyladenine 3-methyladenine results in decreased expression of BECN1 mRNA; 3-methyladenine results in decreased expression of BECN1 protein 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of BECN1]; 3-methyladenine inhibits the reaction [BECN1 protein results in decreased susceptibility to Staurosporine]; 3-methyladenine inhibits the reaction [Caffeine results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [E platinum results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; 3-methyladenine inhibits the reaction [gossypetin promotes the reaction [malondialdehyde-low density lipoprotein, human promotes the reaction [BECN1 protein binds to PIK3C3 protein]]]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide promotes the reaction [BECN1 protein binds to PIK3C3 protein]]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased expression of BECN1 mRNA]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [hydroxyethyl methacrylate results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [LGALS1 protein results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [malondialdehyde-low density lipoprotein, human promotes the reaction [BECN1 protein binds to PIK3C3 protein]]; 3-methyladenine inhibits the reaction [polyphyllin I results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Potassium Iodide results in increased expression of BECN1 mRNA]; 3-methyladenine inhibits the reaction [Potassium Iodide results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [rottlerin results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [Silicon Dioxide promotes the reaction [PIK3C3 protein binds to BECN1 protein]]; 3-methyladenine inhibits the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased expression of BECN1 protein] |
CTD |
PMID:16497721 PMID:18619688 PMID:20525898 PMID:22322152 PMID:22902833 PMID:25110043 PMID:25622137 PMID:26804764 PMID:28025121 PMID:28130038 PMID:28184909 PMID:29518472 PMID:29923297 PMID:30365942 PMID:30555576 PMID:30611790 PMID:30629952 PMID:31421117 PMID:32043704 PMID:32061152 PMID:32687844 PMID:33462182 PMID:33545342 PMID:34051206 PMID:34423507 PMID:35066094 More...
|
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage |
ISO |
3-methyladenine results in increased cleavage of BID protein |
CTD |
PMID:26853465 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [sepantronium results in decreased expression of BIRC5 protein] |
CTD |
PMID:31837377 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression |
ISO |
3-methyladenine results in decreased expression of BNIP3 protein |
CTD |
PMID:26853465 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
EXP ISO |
3-methyladenine promotes the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of CASP1 protein modified form] 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the cleavage of CASP1 protein] 3-methyladenine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased cleavage of CASP1 protein]; 3-methyladenine inhibits the reaction [Patulin results in increased expression of CASP1 protein]; 3-methyladenine promotes the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased cleavage of CASP1 protein] |
CTD |
PMID:27611972 PMID:30205151 PMID:30237538 PMID:31586597 PMID:33217525 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity increases expression |
ISO EXP |
3-methyladenine inhibits the reaction [Acrolein results in increased cleavage of CASP3 protein]; 3-methyladenine inhibits the reaction [Artesunate results in increased cleavage of CASP3 protein]; 3-methyladenine inhibits the reaction [Biological Products results in increased cleavage of CASP3 protein]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein modified form]; 3-methyladenine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of CASP3 protein]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased cleavage of CASP3 protein]; 3-methyladenine inhibits the reaction [perfluorooctane sulfonic acid results in increased activity of CASP3 protein]; 3-methyladenine inhibits the reaction [polyphyllin I results in increased expression of CASP3 protein modified form]; 3-methyladenine inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Amiodarone results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [astin B results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Biological Products results in increased expression of and results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]; 3-methyladenine promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [dihydrocapsaicin results in increased activity of CASP3 protein]; 3-methyladenine promotes the reaction [embelin results in increased degradation of CASP3 protein]; 3-methyladenine promotes the reaction [Fluorouracil results in increased cleavage of and results in increased activity of CASP3 protein]; 3-methyladenine promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [MAP3K5 protein results in increased activity of CASP3 protein]; 3-methyladenine promotes the reaction [Paraquat results in increased activity of CASP3 protein]; 3-methyladenine promotes the reaction [Potassium Dichromate results in increased expression of CASP3 protein modified form]; 3-methyladenine promotes the reaction [tetrandrine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [usnic acid results in increased activity of CASP3 protein]; 3-methyladenine results in increased expression of and results in increased cleavage of CASP3 protein; [3-methyladenine co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [3-methyladenine co-treated with fosbretabulin] results in increased cleavage of CASP3 protein; [3-methyladenine co-treated with Miconazole] results in increased cleavage of CASP3 protein; [3-methyladenine co-treated with vandetanib] results in increased activity of CASP3 protein; ATG5 protein affects the reaction [3-methyladenine results in increased activity of CASP3 protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP3 protein]]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [3-methyladenine promotes the reaction [dihydrocapsaicin results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartic acid inhibits the reaction [dihydrocapsaicin promotes the reaction [3-methyladenine results in increased activity of CASP3 protein]]; benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [3-methyladenine results in increased activity of CASP3 protein]; dihydrocapsaicin promotes the reaction [3-methyladenine results in increased activity of CASP3 protein] 3-methyladenine results in increased cleavage of CASP3 protein 3-methyladenine results in increased expression of CASP3 mRNA 3-methyladenine inhibits the reaction [Alpha-Amanitin results in increased cleavage of CASP3 protein]; 3-methyladenine inhibits the reaction [procyanidin B2 inhibits the reaction [Hydrogen Peroxide results in increased expression of CASP3 mRNA]]; 3-methyladenine promotes the reaction [Fluorouracil results in increased cleavage of and results in increased activity of CASP3 protein] 3-methyladenine inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP3 protein]; 3-methyladenine inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; 3-methyladenine inhibits the reaction [sodium arsenite results in increased activity of CASP3 protein]; 3-methyladenine promotes the reaction [4-nonylphenol results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [Staurosporine results in increased cleavage of CASP3 protein]; 3-methyladenine promotes the reaction [T-2 Toxin results in increased expression of CASP3 protein modified form] |
CTD |
PMID:16497721 PMID:17341480 PMID:18818525 PMID:19116755 PMID:19139269 PMID:20104024 PMID:20426806 PMID:20929985 PMID:21681844 PMID:23380477 PMID:23799852 PMID:23912912 PMID:24321340 PMID:25078063 PMID:25219577 PMID:25266202 PMID:25639566 PMID:25939952 PMID:26804764 PMID:26822499 PMID:26853465 PMID:27057282 PMID:27413105 PMID:28219700 PMID:28483490 PMID:28722333 PMID:28802652 PMID:29902662 PMID:30465897 PMID:30629952 PMID:31226464 PMID:31421117 PMID:32043704 PMID:32569804 PMID:32981224 PMID:33002460 PMID:34374793 PMID:35175747 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases activity |
ISO |
3-methyladenine results in increased activity of CASP4 protein |
CTD |
PMID:20371669 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
multiple interactions increases activity |
ISO |
3-methyladenine promotes the reaction [usnic acid results in increased activity of CASP7 protein] 3-methyladenine results in increased activity of CASP7 protein |
CTD |
PMID:20371669 PMID:25078063 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO |
3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]; 3-methyladenine promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP8 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP8 protein]]] |
CTD |
PMID:20104024 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [Acrolein results in increased cleavage of CASP9 protein]; 3-methyladenine inhibits the reaction [Cannabidiol results in increased activity of CASP9 protein]; 3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased activity of CASP9 protein]]; 3-methyladenine inhibits the reaction [Diosgenin inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP9 protein]]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of CASP9 protein modified form]; 3-methyladenine inhibits the reaction [hydroxyethyl methacrylate results in increased expression of CASP9 mRNA]; 3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [BO-1012 results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]; 3-methyladenine promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]; 3-methyladenine promotes the reaction [embelin results in increased degradation of CASP9 protein]; [3-methyladenine co-treated with Potassium Dichromate] results in increased expression of CASP9 protein modified form; [3-methyladenine co-treated with vandetanib] results in increased activity of CASP9 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [ABT-737 promotes the reaction [Celecoxib results in increased cleavage of CASP9 protein]]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [3-methyladenine promotes the reaction [Celecoxib promotes the reaction [ABT-737 results in increased cleavage of CASP9 protein]]] 3-methyladenine inhibits the reaction [Aminolevulinic Acid analog results in increased activity of CASP9 protein]; 3-methyladenine promotes the reaction [Staurosporine results in increased cleavage of CASP9 protein] |
CTD |
PMID:16497721 PMID:20104024 PMID:20426806 PMID:23799852 PMID:24823293 PMID:28184909 PMID:28722333 PMID:29902662 PMID:31226464 PMID:32569804 PMID:34302491 PMID:35149085 More...
|
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in decreased activity of CAT protein]] |
CTD |
PMID:34051206 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccn1 |
cellular communication network factor 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of CCN1 protein]] |
CTD |
PMID:34405320 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased expression of CDKN1A protein]]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein] |
CTD |
PMID:22927544 PMID:30555576 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdx2 |
caudal type homeo box 2 |
increases expression |
ISO |
3-methyladenine results in increased expression of CDX2 mRNA |
CTD |
PMID:21681844 |
|
NCBI chr12:7,726,798...7,733,142
Ensembl chr12:7,726,798...7,733,142
|
|
G |
Cebpa |
CCAAT/enhancer binding protein alpha |
multiple interactions |
ISO |
[Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in decreased expression of CEBPA mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412
|
|
G |
Chek1 |
checkpoint kinase 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [BO-1012 results in increased phosphorylation of CHEK1 protein] |
CTD |
PMID:24823293 |
|
NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009
|
|
G |
Ckb |
creatine kinase B |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:31419397 |
|
NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315
|
|
G |
Ckm |
creatine kinase, M-type |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [citreoviridin results in increased secretion of [CKM protein binds to CKB protein]] |
CTD |
PMID:31419397 |
|
NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Ethanol promotes the reaction [Mirtazapine results in increased expression of COL1A1 mRNA]]; 3-methyladenine inhibits the reaction [Mirtazapine results in increased expression of COL1A1 mRNA] |
CTD |
PMID:35066094 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of CTSB protein]; 3-methyladenine inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; 3-methyladenine inhibits the reaction [Acrolein results in increased expression of CTSB protein]; 3-methyladenine inhibits the reaction [Patulin results in increased secretion of CTSB protein] |
CTD |
PMID:23380477 PMID:29902662 PMID:30237538 PMID:33217525 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Cadmium Chloride results in increased cleavage of CTSL protein] |
CTD |
PMID:25639782 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cxcl2 |
C-X-C motif chemokine ligand 2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of CXCL2 mRNA]; 3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of CXCL2 protein] |
CTD |
PMID:28867211 |
|
NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of CXCL1 mRNA]; 3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of CXCL1 protein] |
CTD |
PMID:28867211 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions |
ISO |
3-methyladenine promotes the reaction [MAP3K5 protein affects the localization of CYCS protein] |
CTD |
PMID:20929985 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
3-methyladenine promotes the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein] |
CTD |
PMID:28245985 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Potassium Dichromate] results in increased expression of EIF2AK3 protein modified form |
CTD |
PMID:32569804 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
decreases phosphorylation multiple interactions |
EXP ISO |
3-methyladenine results in decreased phosphorylation of EIF4EBP1 protein 3-methyladenine inhibits the reaction [Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of EIF4EBP1 protein]] |
CTD |
PMID:26804764 PMID:35149085 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [sepantronium results in decreased expression of and results in decreased stability of ELAVL1 mRNA]; 3-methyladenine inhibits the reaction [sepantronium results in decreased expression of ELAVL1 protein] |
CTD |
PMID:31837377 |
|
NCBI chr12:2,640,936...2,684,787
Ensembl chr12:2,645,061...2,684,784
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [di-n-propyldithiocarbamate results in decreased expression of FTH1 protein] 3-methyladenine promotes the reaction [erastin results in increased expression of FTH1 protein] |
CTD |
PMID:32687844 PMID:32937103 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Gabarap |
GABA type A receptor-associated protein |
decreases expression |
ISO |
3-methyladenine results in decreased expression of GABARAP mRNA |
CTD |
PMID:21681844 |
|
NCBI chr10:54,714,834...54,717,769
Ensembl chr10:54,714,198...54,717,765
|
|
G |
Gap43 |
growth associated protein 43 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [sodium arsenite results in decreased expression of GAP43] |
CTD |
PMID:25639566 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [[lead acetate results in increased abundance of Lead] which results in decreased expression of GJA1 protein] |
CTD |
PMID:33242459 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases expression |
ISO |
TRP53BP2 protein affects the reaction [3-methyladenine results in increased expression of GPT protein] |
CTD |
PMID:31513885 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:30362509 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gys1 |
glycogen synthase 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of GYS1 protein] |
CTD |
PMID:30362509 |
|
NCBI chr 1:95,915,443...95,935,292
Ensembl chr 1:95,915,443...95,935,292
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [CR 3294 results in decreased expression of HIF1A protein] |
CTD |
PMID:18927491 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of HK2 protein]; 3-methyladenine inhibits the reaction [Potassium Dichromate results in increased expression of HK2 protein] |
CTD |
PMID:32569804 PMID:34481905 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [HMGA2 protein results in decreased expression of COX4 protein]; 3-methyladenine inhibits the reaction [HMGA2 protein results in decreased expression of ND1 protein] |
CTD |
PMID:34481905 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
3-methyladenine promotes the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]; 3-methyladenine promotes the reaction [Potassium Dichromate results in increased expression of HSPA5 protein] |
CTD |
PMID:28245985 PMID:32569804 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] |
CTD |
PMID:24145604 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Patulin results in increased expression of IL18 protein]; 3-methyladenine promotes the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL18 protein] |
CTD |
PMID:30205151 PMID:33217525 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP ISO |
3-methyladenine inhibits the reaction [lead acetate results in increased expression of IL1B protein]; 3-methyladenine promotes the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of IL1B protein modified form] 3-methyladenine affects the reaction [[HU 308 co-treated with Dextran Sulfate] affects the expression of IL1B protein]; 3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]]; TRP53BP2 protein affects the reaction [3-methyladenine results in increased expression of IL1B mRNA] 3-methyladenine inhibits the reaction [[Arsenic Trioxide co-treated with lipopolysaccharide, Escherichia coli O111 B4] results in increased expression of IL1B protein]; 3-methyladenine inhibits the reaction [Patulin results in increased expression of IL1B protein]; 3-methyladenine promotes the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of IL1B protein] |
CTD |
PMID:27611972 PMID:30205151 PMID:30237538 PMID:31513885 PMID:31586597 PMID:32879255 PMID:33217525 PMID:34051206 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
3-methyladenine inhibits the reaction [1-nitropyrene results in increased secretion of IL6 protein]; 3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]]; [Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in increased secretion of IL6 protein]; TRP53BP2 protein affects the reaction [3-methyladenine results in increased expression of IL6 mRNA] 3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of IL6 mRNA]; 3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein] |
CTD |
PMID:28867211 PMID:29078374 PMID:31513885 PMID:34051206 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irs1 |
insulin receptor substrate 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of IRS1 protein] |
CTD |
PMID:30362509 |
|
NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased expression of ITGAM protein]; 3-methyladenine inhibits the reaction [Tretinoin affects the localization of ITGAM protein]; 3-methyladenine inhibits the reaction [Tretinoin results in increased localization of and results in increased expression of ITGAM protein]; [benzyloxycarbonyl-valyl-alanyl-aspartic acid analog co-treated with 3-methyladenine] inhibits the reaction [Tretinoin affects the localization of ITGAM protein] |
CTD |
PMID:20574048 PMID:28130038 PMID:29743969 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
3-methyladenine co-treated with anlotinib decreases phosphorylation of JAK2 protein in lung epithelium |
RGD |
PMID:30755242 |
RGD:149735343 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Doxorubicin results in decreased expression of LAMP1 protein] 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of LAMP1 mRNA]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of LAMP1 protein] |
CTD |
PMID:31226464 PMID:33462182 |
|
NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Doxorubicin results in decreased expression of LAMP2 protein] |
CTD |
PMID:31226464 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Ldha |
lactate dehydrogenase A |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of LDHA protein]; 3-methyladenine inhibits the reaction [Potassium Dichromate results in increased expression of LDHA protein] |
CTD |
PMID:32569804 PMID:34481905 |
|
NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472
|
|
G |
Lgals1 |
galectin 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [LGALS1 protein results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [LGALS1 protein results in decreased susceptibility to Cisplatin]; 3-methyladenine inhibits the reaction [LGALS1 protein results in increased expression of BECN1 protein]; 3-methyladenine inhibits the reaction [LGALS1 protein results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:30365942 |
|
NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [LRRK2 gene mutant form results in increased susceptibility to 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:25017139 |
|
NCBI chr 7:122,826,712...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions affects metabolic processing |
ISO |
3-methyladenine inhibits the reaction [sodium arsenite results in increased expression of MAP1LC3A protein modified form] 3-methyladenine affects the metabolism of MAP1LC3A protein |
CTD |
PMID:20008137 PMID:21742779 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases lipidation increases expression decreases expression decreases cleavage affects metabolic processing |
EXP ISO |
3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; 3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in decreased expression of MAP1LC3B protein]]; 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form]; 3-methyladenine results in decreased expression of and results in decreased cleavage of MAP1LC3B protein 3-methyladenine results in increased lipidation of MAP1LC3B protein 3-methyladenine results in increased expression of MAP1LC3B protein modified form 3-methyladenine results in decreased expression of MAP1LC3B mRNA 3-methyladenine results in decreased cleavage of MAP1LC3B protein 3-methyladenine affects the metabolism of MAP1LC3B protein 3-methyladenine inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form]; 3-methyladenine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Dibutyl Phthalate results in increased cleavage of MAP1LC3B protein]; cupric chloride inhibits the reaction [3-methyladenine results in decreased expression of MAP1LC3B protein modified form] 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Artesunate results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein modified form]; 3-methyladenine inhibits the reaction [Caffeine results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of and results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [E platinum results in increased expression of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [E platinum results in increased metabolism of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [flavokawain B results in increased expression of MAP1LC3B protein modified form]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased expression of MAP1LC3B mRNA]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in increased expression of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Ivermectin results in increased expression of and results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [LGALS1 protein results in increased expression of MAP1LC3B protein modified form]; 3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Quercetin results in increased cleavage of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [sepantronium results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; 3-methyladenine inhibits the reaction [Vorinostat results in increased expression of MAP1LC3B protein modified form]; [3-methyladenine co-treated with TNF protein] results in decreased expression of MAP1LC3B protein alternative form; [bisphenol A co-treated with 3-methyladenine] results in increased lipidation of MAP1LC3B protein; Cadmium Chloride promotes the reaction [3-methyladenine results in increased expression of MAP1LC3B protein modified form] 3-methyladenine results in decreased expression of MAP1LC3B mRNA; 3-methyladenine results in decreased expression of MAP1LC3B protein modified form |
CTD |
PMID:18640276 PMID:20962572 PMID:21325019 PMID:21681844 PMID:22322152 PMID:23680031 PMID:24145604 PMID:25639782 PMID:26804720 PMID:28251795 PMID:28867211 PMID:29128638 PMID:29518472 PMID:30025493 PMID:30365942 PMID:30555576 PMID:30611790 PMID:30677399 PMID:31837377 PMID:32043704 PMID:32512069 PMID:32687844 PMID:32937103 PMID:33002460 PMID:34281243 PMID:34580807 PMID:34634291 PMID:34904774 PMID:35149085 PMID:35472370 More...
|
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map3k5 |
mitogen-activated protein kinase kinase kinase 5 |
affects response to substance multiple interactions |
ISO |
3-methyladenine affects the susceptibility to MAP3K5 protein 3-methyladenine inhibits the reaction [MAP3K5 protein results in decreased phosphorylation of MTOR protein]; 3-methyladenine promotes the reaction [MAP3K5 protein affects the localization of CYCS protein]; 3-methyladenine promotes the reaction [MAP3K5 protein results in increased activity of CASP3 protein] |
CTD |
PMID:20929985 |
|
NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases expression |
ISO |
3-methyladenine inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; Cadmium Chloride promotes the reaction [3-methyladenine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [3-methyladenine results in increased phosphorylation of MAPK1 protein]; U 0126 inhibits the reaction [Cadmium Chloride promotes the reaction [3-methyladenine results in increased phosphorylation of MAPK1 protein]] 3-methyladenine results in increased expression of MAPK1 protein modified form |
CTD |
PMID:28483490 PMID:34580807 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases expression increases phosphorylation multiple interactions |
ISO |
3-methyladenine results in increased expression of MAPK3 protein modified form 3-methyladenine results in increased phosphorylation of MAPK3 protein 3-methyladenine inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; Cadmium Chloride promotes the reaction [3-methyladenine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [3-methyladenine results in increased phosphorylation of MAPK3 protein]; U 0126 inhibits the reaction [Cadmium Chloride promotes the reaction [3-methyladenine results in increased phosphorylation of MAPK3 protein]] |
CTD |
PMID:28483490 PMID:34580807 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [sepantronium results in decreased expression of MCL1 protein]; 3-methyladenine promotes the reaction [usnic acid results in decreased expression of MCL1 protein] |
CTD |
PMID:25078063 PMID:31837377 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Hydrogen Peroxide results in decreased expression of MMP9 protein]; 3-methyladenine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]] |
CTD |
PMID:24145604 PMID:32043704 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpg |
N-methylpurine-DNA glycosylase |
increases metabolic processing |
ISO |
MPG protein results in increased metabolism of 3-methyladenine |
CTD |
PMID:10626224 |
|
NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,395,782...15,402,520
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [lead acetate results in increased expression of MPO protein] |
CTD |
PMID:32879255 |
|
NCBI chr10:72,594,458...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt-nd1 |
mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [HMGA2 protein results in decreased expression of ND1 protein] |
CTD |
PMID:34481905 |
|
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation increases phosphorylation multiple interactions increases expression |
EXP ISO |
3-methyladenine results in decreased phosphorylation of MTOR protein 3-methyladenine results in increased phosphorylation of MTOR protein 3-methyladenine inhibits the reaction [Arsenic Trioxide results in decreased phosphorylation of MTOR protein] 3-methyladenine results in increased expression of MTOR protein 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of MTOR protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of MTOR protein]; 3-methyladenine inhibits the reaction [Diosgenin promotes the reaction [alpha-Chlorohydrin results in decreased phosphorylation of MTOR protein]]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of MTOR protein]; 3-methyladenine inhibits the reaction [MAP3K5 protein results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:20929985 PMID:26804764 PMID:29518472 PMID:32043704 PMID:33462182 PMID:35149085 More...
|
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Nanog |
Nanog homeobox |
increases expression |
ISO |
3-methyladenine results in increased expression of NANOG mRNA |
CTD |
PMID:21681844 |
|
NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [di-n-propyldithiocarbamate results in increased expression of NCOA4 protein] 3-methyladenine inhibits the reaction [erastin results in decreased expression of NCOA4 protein] |
CTD |
PMID:32687844 PMID:32937103 |
|
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Ndufa1 |
NADH:ubiquinone oxidoreductase subunit A1 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA1 mRNA] [Taurine co-treated with 3-methyladenine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA1 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633
|
|
G |
Ndufa2 |
NADH:ubiquinone oxidoreductase subunit A2 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA2 mRNA] 3-methyladenine inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA2 mRNA]; Taurine promotes the reaction [3-methyladenine inhibits the reaction [1-nitropyrene results in decreased expression of NDUFA2 mRNA]] |
CTD |
PMID:29078374 |
|
NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076
|
|
G |
Ndufc2 |
NADH:ubiquinone oxidoreductase subunit C2 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFC2 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 1:151,711,965...151,718,188
Ensembl chr 1:151,711,901...151,718,189
|
|
G |
Ndufs3 |
NADH:ubiquinone oxidoreductase core subunit S3 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Chlorpyrifos results in decreased expression of NDUFS3 protein] |
CTD |
PMID:26070385 |
|
NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824
|
|
G |
Ndufs4 |
NADH:ubiquinone oxidoreductase subunit S4 |
multiple interactions |
ISO |
[3-methyladenine co-treated with Taurine] inhibits the reaction [1-nitropyrene results in decreased expression of NDUFS4 mRNA] |
CTD |
PMID:29078374 |
|
NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846
|
|
G |
Nefh |
neurofilament heavy chain |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [tri-o-cresyl phosphate results in decreased expression of NEFH protein] |
CTD |
PMID:23743148 |
|
NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351
|
|
G |
Nefl |
neurofilament light chain |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [tri-o-cresyl phosphate results in decreased expression of NEFL protein] |
CTD |
PMID:23743148 |
|
NCBI chr15:42,301,920...42,305,793
Ensembl chr15:42,301,916...42,305,793
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; 3-methyladenine inhibits the reaction [Patulin results in increased expression of NLRP3 protein]; 3-methyladenine promotes the reaction [[Acrolein co-treated with Lipopolysaccharides] results in increased expression of NLRP3 protein] |
CTD |
PMID:30205151 PMID:33217525 PMID:34423507 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [Ethanol promotes the reaction [Mirtazapine results in increased expression of NPPB mRNA]]; 3-methyladenine inhibits the reaction [Mirtazapine results in increased expression of NPPB mRNA] |
CTD |
PMID:35066094 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
3-methyladenine inhibits the reaction [Artesunate results in increased cleavage of PARP1 protein]; 3-methyladenine inhibits the reaction [divinyl sulfone analog results in increased cleavage of PARP1 protein]; 3-methyladenine inhibits the reaction [Fingolimod Hydrochloride results in increased cleavage of PARP1 protein]; 3-methyladenine inhibits the reaction [Morpholines analog results in increased cleavage of PARP1 protein]; 3-methyladenine inhibits the reaction [Oligopeptides analog results in increased cleavage of PARP1 protein]; 3-methyladenine inhibits the reaction [polyphyllin I results in increased expression of PARP1 protein modified form]; 3-methyladenine inhibits the reaction [Resveratrol inhibits the reaction [Rotenone results in increased cleavage of PARP1 protein]]; 3-methyladenine promotes the reaction [BO-1012 results in increased cleavage of PARP1 protein]; 3-methyladenine promotes the reaction [embelin results in increased cleavage of PARP1 protein]; 3-methyladenine promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; 3-methyladenine promotes the reaction [Fluorouracil results in increased cleavage of and results in increased activity of PARP1 protein]; 3-methyladenine promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; [3-methyladenine co-treated with Amiodarone] results in increased cleavage of PARP1 protein; [3-methyladenine co-treated with fosbretabulin] results in increased cleavage of PARP1 protein; [Chloroquine co-treated with 3-methyladenine] results in increased cleavage of PARP1 protein; [flavokawain B co-treated with 3-methyladenine] results in increased cleavage of PARP1 protein 3-methyladenine inhibits the reaction [aristolochic acid I results in increased cleavage of PARP1 protein]; 3-methyladenine promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] 3-methyladenine results in increased cleavage of PARP1 protein |
CTD |
PMID:19116755 PMID:21616090 PMID:21778691 PMID:23912912 PMID:23939141 PMID:24321340 PMID:24823293 PMID:24875536 PMID:25939952 PMID:28722333 PMID:30025493 PMID:31421117 PMID:33002460 PMID:34374793 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pik3c3 |
phosphatidylinositol 3-kinase, catalytic subunit type 3 |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [gossypetin promotes the reaction [malondialdehyde-low density lipoprotein, human promotes the reaction [BECN1 protein binds to PIK3C3 protein]]]; 3-methyladenine inhibits the reaction [gossypetin promotes the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PIK3C3 protein]]; 3-methyladenine inhibits the reaction [Hydrogen Peroxide promotes the reaction [BECN1 protein binds to PIK3C3 protein]]; 3-methyladenine inhibits the reaction [malondialdehyde-low density lipoprotein, human promotes the reaction [BECN1 protein binds to PIK3C3 protein]]; 3-methyladenine inhibits the reaction [malondialdehyde-low density lipoprotein, human results in increased expression of PIK3C3 protein]; 3-methyladenine inhibits the reaction [Silicon Dioxide promotes the reaction [PIK3C3 protein binds to BECN1 protein]]; [3-methyladenine results in decreased activity of PIK3C3 protein] which results in decreased susceptibility to Hydrogen Peroxide 3-methyladenine inhibits the reaction [Ethanol promotes the reaction [Mirtazapine results in increased expression of PIK3C3 protein]]; 3-methyladenine inhibits the reaction [Mirtazapine results in increased expression of PIK3C3 protein] |
CTD |
PMID:20525898 PMID:21742779 PMID:25622137 PMID:32061152 PMID:35066094 |
|
NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048
|
|
G |
Pik3r1 |
phosphoinositide-3-kinase regulatory subunit 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of PIK3R1 protein] |
CTD |
PMID:32043704 |
|
NCBI chr 2:32,878,942...32,963,611
Ensembl chr 2:32,882,032...32,963,631
|
|
G |
Pkm |
pyruvate kinase M1/2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of PKM protein]; 3-methyladenine inhibits the reaction [Potassium Dichromate results in increased expression of PKM protein] |
CTD |
PMID:32569804 PMID:34481905 |
|
NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599
|
|
G |
Pml |
PML nuclear body scaffold |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr 8:58,627,347...58,661,927
Ensembl chr 8:58,628,837...58,658,971
|
|
G |
Pou5f1 |
POU class 5 homeobox 1 |
increases expression |
ISO |
3-methyladenine results in increased expression of POU5F1 protein |
CTD |
PMID:21681844 |
|
NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Arsenic Trioxide results in increased expression of PPARA protein] |
CTD |
PMID:30677399 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]] |
CTD |
PMID:24145604 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pycard |
PYD and CARD domain containing |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]] |
CTD |
PMID:34423507 |
|
NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955
|
|
G |
Rara |
retinoic acid receptor, alpha |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [4-amino-2-trifluoromethyl-phenyl retinate results in increased degradation of [PML protein mutant form binds to RARA protein mutant form]] |
CTD |
PMID:28130038 |
|
NCBI chr10:83,883,490...83,928,932
Ensembl chr10:83,893,384...83,928,142
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO EXP |
3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of RELA protein modified form]; 3-methyladenine inhibits the reaction [Particulate Matter results in increased expression of RELA protein] 3-methyladenine promotes the reaction [Zearalenone results in increased phosphorylation of and affects the localization of RELA protein] |
CTD |
PMID:28867211 PMID:31586597 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation increases phosphorylation multiple interactions |
EXP ISO |
3-methyladenine results in decreased phosphorylation of RPS6KB1 protein 3-methyladenine results in increased phosphorylation of RPS6KB1 protein 3-methyladenine inhibits the reaction [[Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:26804764 PMID:35149085 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of SLC2A1 protein]; 3-methyladenine inhibits the reaction [Potassium Dichromate results in increased expression of SLC2A1 protein] |
CTD |
PMID:32569804 PMID:34481905 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Snca |
synuclein alpha |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Rotenone results in decreased expression of SNCA mRNA]; 3-methyladenine inhibits the reaction [Rotenone results in decreased expression of SNCA protein] |
CTD |
PMID:27133439 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sox2 |
SRY-box transcription factor 2 |
increases expression |
ISO |
3-methyladenine results in increased expression of SOX2 mRNA |
CTD |
PMID:21681844 |
|
NCBI chr 2:117,536,929...117,539,338
Ensembl chr 2:117,536,929...117,539,338
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO EXP |
3-methyladenine results in increased expression of SQSTM1 protein 3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein] 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Ethanol promotes the reaction [Mirtazapine results in increased expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [fenvalerate results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Mirtazapine results in increased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide inhibits the reaction [Glucose results in increased expression of SQSTM1 protein]] 3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased degradation of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Ivermectin results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [LGALS1 protein results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Potassium Dichromate results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Potassium Iodide results in increased expression of SQSTM1 mRNA]; 3-methyladenine inhibits the reaction [Potassium Iodide results in increased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Quercetin results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; 3-methyladenine inhibits the reaction [sepantronium results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [Silicon Dioxide results in decreased expression of SQSTM1 protein]; 3-methyladenine inhibits the reaction [tris(1,3-dichloro-2-propyl)phosphate results in increased degradation of SQSTM1 protein]; 3-methyladenine promotes the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; [3-methyladenine co-treated with bisphenol A] results in increased expression of SQSTM1 protein |
CTD |
PMID:20574048 PMID:22927544 PMID:24833599 PMID:25943029 PMID:28025121 PMID:28251795 PMID:29128638 PMID:29307831 PMID:29518472 PMID:29923297 PMID:30362509 PMID:30365942 PMID:31734597 PMID:31837377 PMID:32061152 PMID:32569804 PMID:32702505 PMID:33462182 PMID:34051206 PMID:34281243 PMID:34405320 PMID:34423507 PMID:34481905 PMID:34580807 PMID:34904774 PMID:35066094 More...
|
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [fenvalerate results in decreased expression of TH protein]; 3-methyladenine inhibits the reaction [Oxidopamine results in decreased expression of TH protein] |
CTD |
PMID:28802652 PMID:31734597 |
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases expression |
ISO EXP |
3-methyladenine inhibits the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; 3-methyladenine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; 3-methyladenine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; 3-methyladenine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; [3-methyladenine co-treated with TNF protein] results in decreased expression of MAP1LC3B protein alternative form 3-methyladenine inhibits the reaction [anemoside B4 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]] 3-methyladenine results in increased expression of TNF mRNA 3-methyladenine inhibits the reaction [lead acetate results in increased expression of TNF protein]; 3-methyladenine promotes the reaction [[Zearalenone co-treated with Lipopolysaccharides] results in increased expression of TNF protein] |
CTD |
PMID:24145604 PMID:31513885 PMID:31586597 PMID:32879255 PMID:34051206 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnnt2 |
troponin T2, cardiac type |
multiple interactions |
EXP |
3-methyladenine inhibits the reaction [citreoviridin results in increased secretion of TNNT2 protein] |
CTD |
PMID:31419397 |
|
NCBI chr13:47,267,325...47,285,390
Ensembl chr13:47,267,204...47,285,388
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [Doxorubicin results in decreased expression of TOMM20 protein] |
CTD |
PMID:31226464 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
3-methyladenine inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TP53 protein]]; 3-methyladenine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein]; [3-methyladenine co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein 3-methyladenine inhibits the reaction [Caffeine inhibits the reaction [2,2'-azobis(2-amidinopropane) results in increased phosphorylation of TRP53 protein]] |
CTD |
PMID:22927544 PMID:23380477 PMID:30555576 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tp53bp2 |
tumor protein p53 binding protein, 2 |
multiple interactions |
ISO |
TRP53BP2 protein affects the reaction [3-methyladenine results in increased expression of GPT protein]; TRP53BP2 protein affects the reaction [3-methyladenine results in increased expression of IL1B mRNA]; TRP53BP2 protein affects the reaction [3-methyladenine results in increased expression of IL6 mRNA] |
CTD |
PMID:31513885 |
|
NCBI chr13:94,088,769...94,145,436
Ensembl chr13:94,088,709...94,145,432
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions increases phosphorylation |
EXP ISO |
3-methyladenine affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]]; 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; 3-methyladenine inhibits the reaction [2,5,2',5'-tetrachlorobiphenyl results in increased expression of ULK1 protein] 3-methyladenine results in increased phosphorylation of ULK1 protein 3-methyladenine inhibits the reaction [2,4,4'-trichlorobiphenyl results in increased expression of ULK1 protein]; 3-methyladenine inhibits the reaction [[Diosgenin co-treated with alpha-Chlorohydrin] results in decreased phosphorylation of ULK1 protein] |
CTD |
PMID:29128638 PMID:29518472 PMID:35149085 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [AGT protein affects the localization of Calcium] |
CTD |
PMID:21613610 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Aim2 |
absent in melanoma 2 |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of AIM2 protein |
CTD |
PMID:32645460 |
|
NCBI chr13:85,865,206...85,906,996
Ensembl chr13:85,866,284...85,906,975
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Alb |
albumin |
decreases uptake |
ISO |
bafilomycin A1 results in decreased uptake of ALB protein |
CTD |
PMID:16313995 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of APAF1 protein |
CTD |
PMID:28483490 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Asic1 |
acid sensing ion channel subunit 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Freund's Adjuvant results in increased expression of ASIC1 mRNA] |
CTD |
PMID:16769263 |
|
NCBI chr 7:130,798,317...130,828,535
Ensembl chr 7:130,799,917...130,828,541
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]] |
CTD |
PMID:29938581 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] |
CTD |
PMID:12813466 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased expression of BCL2 mRNA bafilomycin A1 promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein] |
CTD |
PMID:31310755 PMID:34374793 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Becn1 |
beclin 1 |
multiple interactions increases expression |
ISO EXP |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of BECN1 protein] [Swainsonine co-treated with bafilomycin A1] results in increased expression of BECN1 protein; bafilomycin A1 promotes the reaction [[lead acetate results in increased abundance of Lead] which results in increased expression of BECN1 protein] bafilomycin A1 results in increased expression of BECN1 protein |
CTD |
PMID:32645460 PMID:33186601 PMID:33242459 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions increases cleavage increases expression |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein] bafilomycin A1 results in increased cleavage of BID protein vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of BID protein] bafilomycin A1 results in increased expression of BID protein modified form |
CTD |
PMID:26853465 PMID:28378122 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
ISO |
BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; capivasertib affects the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; Gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein]; HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; Lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; vistusertib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] bafilomycin A1 results in increased expression of BNIP3 mRNA; bafilomycin A1 results in increased expression of BNIP3 protein |
CTD |
PMID:25981168 PMID:26853465 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases activity decreases activity multiple interactions |
ISO EXP |
bafilomycin A1 results in increased cleavage of CASP3 protein bafilomycin A1 results in increased activity of CASP3 protein bafilomycin A1 results in decreased activity of CASP3 protein bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein] [Swainsonine co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of CASP3 protein modified form]; bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] [bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein; [bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; [bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein; [Cannabidiol co-treated with bafilomycin A1] results in increased cleavage of CASP3 protein; bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP3 protein]; bafilomycin A1 inhibits the reaction [tetrandrine results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of CASP3 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased activity of CASP3 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with Cannabidiol] results in increased cleavage of CASP3 protein]; tin protoporphyrin IX inhibits the reaction [[bafilomycin A1 co-treated with methanandamide] results in increased cleavage of CASP3 protein]; vistusertib affects the reaction [bafilomycin A1 results in increased cleavage of CASP3 protein] |
CTD |
PMID:20876807 PMID:23380477 PMID:24321340 PMID:24889822 PMID:25266202 PMID:25981168 PMID:26853465 PMID:28063998 PMID:28378122 PMID:29111403 PMID:30240709 PMID:32708634 PMID:33076330 PMID:33186601 PMID:34374793 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases activity |
ISO |
bafilomycin A1 results in increased activity of CASP4 protein |
CTD |
PMID:20371669 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp7 |
caspase 7 |
increases activity decreases activity |
ISO |
bafilomycin A1 results in increased activity of CASP7 protein bafilomycin A1 results in decreased activity of CASP7 protein |
CTD |
PMID:20371669 PMID:25981168 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein] bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] |
CTD |
PMID:28378122 PMID:29111403 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] bafilomycin A1 inhibits the reaction [Soot analog results in increased expression of CASP9 protein] |
CTD |
PMID:28378122 PMID:30240709 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of CCND1 protein] |
CTD |
PMID:33359579 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdc25c |
cell division cycle 25C |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [xanthatin results in decreased stability of CDC25C protein] |
CTD |
PMID:29074359 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Ctsb |
cathepsin B |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein]; bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] |
CTD |
PMID:12813466 PMID:23380477 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; bafilomycin A1 inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:26682054 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression multiple interactions |
EXP |
bafilomycin A1 results in increased expression of DDIT4 protein [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein |
CTD |
PMID:22689575 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
EXP |
[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine; [bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Aspartic Acid; [bafilomycin A1 co-treated with EGF protein] results in increased abundance of Taurine; [EGF protein co-treated with bafilomycin A1] results in increased expression of DDIT4 protein; bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Arginine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Asparagine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Isoleucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Leucine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Lysine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Methionine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Ornithine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Phenylalanine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Tyrosine]; Cycloheximide inhibits the reaction [[bafilomycin A1 co-treated with EGF protein] results in decreased abundance of Valine] |
CTD |
PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Arsenic Trioxide results in decreased expression of EGFR protein] |
CTD |
PMID:30237564 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Epor |
erythropoietin receptor |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Aristolochic Acids results in increased degradation of and results in decreased expression of EPOR protein] |
CTD |
PMID:26136230 |
|
NCBI chr 8:20,489,678...20,494,257
Ensembl chr 8:20,489,678...20,494,257
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO EXP |
bafilomycin A1 inhibits the reaction [FASL protein affects the localization of Calcium] bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of FASLG protein] |
CTD |
PMID:20200208 PMID:28378122 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fmc1 |
formation of mitochondrial complex V assembly factor 1 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Carbonyl Cyanide m-Chlorophenyl Hydrazone results in decreased expression of FMC1 protein] |
CTD |
PMID:29371327 |
|
NCBI chr 4:67,274,104...67,282,140
Ensembl chr 4:67,274,104...67,282,140
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in increased acetylation of FOXO1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of GJA1 protein |
CTD |
PMID:35750204 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
multiple interactions increases expression |
ISO |
HIF1A mutant form inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 mRNA]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; lapatinib inhibits the reaction [bafilomycin A1 results in increased expression of HIF1A protein] |
CTD |
PMID:25981168 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hmox1 |
heme oxygenase 1 |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of HMOX1 protein [bafilomycin A1 co-treated with methanandamide] results in increased expression of HMOX1 protein; [bafilomycin A1 co-treated with tin protoporphyrin IX] promotes the reaction [Cannabidiol results in increased expression of HMOX1 protein]; bafilomycin A1 inhibits the reaction [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole results in increased expression of HMOX1 protein] |
CTD |
PMID:29796178 PMID:33076330 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ifng |
interferon gamma |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of IFNG mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
bafilomycin A1 results in decreased expression of IL1B mRNA [bafilomycin A1 co-treated with [sodium arsenite results in increased abundance of Arsenic]] results in increased expression of IL1B protein; bafilomycin A1 inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with aluminum sulfate] results in increased secretion of IL1B protein] |
CTD |
PMID:16932910 PMID:24158569 PMID:32645460 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
bafilomycin A1 results in increased expression of IL6 mRNA |
CTD |
PMID:16932910 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
EXP ISO |
bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of EIF4EBP1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] bafilomycin A1 promotes the reaction [Palmitic Acid inhibits the reaction [INS1 protein results in increased uptake of 2-(N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-2-deoxyglucose]] |
CTD |
PMID:22689575 PMID:32283200 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Keap1 |
Kelch-like ECH-associated protein 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]] |
CTD |
PMID:35123989 |
|
NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
increases response to substance |
ISO |
LRRK2 gene mutant form results in increased susceptibility to bafilomycin A1 |
CTD |
PMID:25017139 |
|
NCBI chr 7:122,826,712...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [Uranium results in increased expression of MAP1LC3A protein] bafilomycin A1 results in increased expression of MAP1LC3A protein modified form |
CTD |
PMID:30871063 PMID:31120128 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
increases expression increases lipidation multiple interactions increases cleavage decreases degradation |
ISO EXP |
bafilomycin A1 results in increased expression of MAP1LC3B protein; bafilomycin A1 results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 results in increased expression of MAP1LC3B protein modified form bafilomycin A1 results in increased lipidation of MAP1LC3B protein [Doxorubicin co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein; [Glycyrrhizic Acid co-treated with bafilomycin A1] results in increased lipidation of MAP1LC3B protein; bafilomycin A1 promotes the reaction [C1QTNF9 protein results in increased expression of MAP1LC3B protein modified form] bafilomycin A1 promotes the reaction [Triiodothyronine results in increased lipidation of MAP1LC3B protein]; Triiodothyronine promotes the reaction [bafilomycin A1 results in increased lipidation of MAP1LC3B protein] bafilomycin A1 results in increased cleavage of MAP1LC3B protein bafilomycin A1 results in decreased degradation of MAP1LC3B protein modified form [bafilomycin A1 co-treated with Miconazole] results in increased expression of MAP1LC3B protein; [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] results in increased expression of MAP1LC3B mRNA; [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; Acetylcysteine inhibits the reaction [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]]; ATG5 protein affects the reaction [bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]]; bafilomycin A1 affects the reaction [Ammonium Chloride results in increased metabolism of MAP1LC3B protein]; bafilomycin A1 affects the reaction [AZD4547 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 affects the reaction [AZD8186 affects the expression of MAP1LC3B protein modified form]; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [[alpha-Chlorohydrin co-treated with Diosgenin] results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [capivasertib results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Curcumin results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [gossypol acetic acid results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [metarrestin results in increased expression of MAP1LC3B protein modified form]; bafilomycin A1 promotes the reaction [Miconazole results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [Resveratrol results in increased expression of MAP1LC3B protein alternative form]; bafilomycin A1 promotes the reaction [Sevoflurane results in increased lipidation of MAP1LC3B protein]; bafilomycin A1 promotes the reaction [vistusertib results in increased expression of MAP1LC3B protein modified form]; di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone promotes the reaction [bafilomycin A1 results in increased expression of MAP1LC3B protein]; Resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] |
CTD |
PMID:23880069 PMID:24145604 PMID:25301941 PMID:26459185 PMID:26853465 PMID:27305347 PMID:29248574 PMID:29524503 PMID:29908302 PMID:29938581 PMID:30209975 PMID:31310755 PMID:32278738 PMID:32525084 PMID:32981224 PMID:34580807 PMID:34634291 PMID:35149085 PMID:35472370 More...
|
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK1 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK1 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK1 protein] bafilomycin A1 results in increased expression of MAPK1 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [Capsaicin results in increased activity of MAPK3 protein]; bafilomycin A1 inhibits the reaction [Iron Compounds results in increased expression of MAPK3 protein modified form]; bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased phosphorylation of MAPK3 protein] bafilomycin A1 results in increased expression of MAPK3 protein modified form |
CTD |
PMID:20371669 PMID:28483490 PMID:32645460 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
increases phosphorylation |
ISO |
bafilomycin A1 results in increased phosphorylation of MAPK8 protein |
CTD |
PMID:31310755 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation |
ISO |
bafilomycin A1 results in decreased phosphorylation of MTOR protein |
CTD |
PMID:31310755 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression |
ISO |
bafilomycin A1 results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
NDRG1 protein results in decreased susceptibility to [di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone co-treated with bafilomycin A1] |
CTD |
PMID:24532803 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[Particulate Matter co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [[Silicon Dioxide co-treated with Vitamin D] results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Particulate Matter results in increased expression of NFE2L2 protein]; bafilomycin A1 promotes the reaction [Silicon Dioxide results in increased expression of NFE2L2 protein] bafilomycin A1 results in increased expression of NFE2L2 protein |
CTD |
PMID:30698894 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions increases expression |
ISO |
bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of NLRP3 protein] bafilomycin A1 results in increased expression of NLRP3 protein |
CTD |
PMID:32645460 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nr5a1 |
nuclear receptor subfamily 5, group A, member 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of NR5A1 protein |
CTD |
PMID:29524503 |
|
NCBI chr 3:22,464,786...22,486,328
Ensembl chr 3:22,465,502...22,486,328
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage increases expression |
ISO EXP |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [Atorvastatin results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [brazilin results in increased expression of PARP1 protein modified form]; bafilomycin A1 promotes the reaction [Flavanones results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; BNIP3 mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; HIF1A mutant form promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein] bafilomycin A1 promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] bafilomycin A1 results in increased expression of PARP1 protein modified form bafilomycin A1 inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] |
CTD |
PMID:20876807 PMID:21616090 PMID:24321340 PMID:25981168 PMID:28063998 PMID:29111403 PMID:31310755 PMID:34374793 PMID:35022897 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of PCNA mRNA] |
CTD |
PMID:33359579 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
bafilomycin A1 affects the localization of and results in increased activity of RELA protein |
CTD |
PMID:10339586 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions |
ISO EXP |
bafilomycin A1 results in decreased phosphorylation of RPS6KB1 protein bafilomycin A1 inhibits the reaction [EGF protein results in increased activity of and results in increased phosphorylation of RPS6KB1 protein]; bafilomycin A1 inhibits the reaction [INS protein results in increased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:22689575 PMID:31310755 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Sirt1 |
sirtuin 1 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [resveratrol inhibits the reaction [Hydrogen Peroxide results in decreased expression of SIRT1 protein]] |
CTD |
PMID:24889822 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Slc17a7 |
solute carrier family 17 member 7 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Excitatory Amino Acid Agents]; bafilomycin A1 inhibits the reaction [SLC17A7 protein results in increased uptake of Zinc]; bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 1:95,649,709...95,661,591
Ensembl chr 1:95,649,745...95,661,588
|
|
G |
Slc30a3 |
solute carrier family 30 member 3 |
multiple interactions |
EXP |
bafilomycin A1 inhibits the reaction [SLC30A3 protein promotes the reaction [SLC17A7 protein results in increased uptake of Zinc]] |
CTD |
PMID:15860731 |
|
NCBI chr 6:25,264,310...25,284,720
Ensembl chr 6:25,275,528...25,284,720
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of SNAI1 protein] bafilomycin A1 results in increased expression of SNAI1 protein |
CTD |
PMID:32645460 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases expression |
ISO |
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SNCA protein bafilomycin A1 results in increased expression of SNCA protein |
CTD |
PMID:26031332 |
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sort1 |
sortilin 1 |
decreases expression |
ISO |
bafilomycin A1 results in decreased expression of SORT1 protein |
CTD |
PMID:25805502 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO EXP |
[bafilomycin A1 co-treated with Rotenone] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [Resveratrol inhibits the reaction [Streptozocin results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Sirolimus results in decreased expression of SQSTM1 protein]; decamethrin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; Streptozocin promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] bafilomycin A1 promotes the reaction [Hydrogen Peroxide results in increased expression of SQSTM1 protein] [Resveratrol co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; [Vitamin D co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; bafilomycin A1 inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Dexamethasone results in decreased expression of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of SQSTM1 protein]]; bafilomycin A1 inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; bafilomycin A1 inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [metarrestin results in decreased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [Miconazole results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; bafilomycin A1 promotes the reaction [pachastrissamine analog promotes the reaction [KEAP1 protein binds to SQSTM1 protein]]; Fingolimod Hydrochloride affects the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein]; sodium arsenite promotes the reaction [bafilomycin A1 results in increased expression of SQSTM1 protein] |
CTD |
PMID:21778691 PMID:21858812 PMID:23151917 PMID:24145604 PMID:24238063 PMID:24889822 PMID:25939952 PMID:25943029 PMID:26031332 PMID:27305347 PMID:28125038 PMID:29248574 PMID:29524503 PMID:30698894 PMID:32186374 PMID:32645460 PMID:32981224 PMID:33359579 PMID:34405320 PMID:34520793 PMID:34580807 PMID:35123989 More...
|
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tbk1 |
TANK-binding kinase 1 |
multiple interactions |
ISO |
bafilomycin A1 promotes the reaction [Lipopolysaccharides results in increased phosphorylation of TBK1 protein]; bafilomycin A1 promotes the reaction [Poly I-C results in increased phosphorylation of TBK1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr 7:57,077,830...57,110,868
Ensembl chr 7:57,077,830...57,110,892
|
|
G |
Tlr8 |
toll-like receptor 8 |
multiple interactions |
ISO |
bafilomycin A1 inhibits the reaction [resiquimod results in increased activity of TLR8 protein] |
CTD |
PMID:21398612 |
|
NCBI chr X:27,091,780...27,116,092
Ensembl chr X:27,091,778...27,116,549
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
bafilomycin A1 results in increased expression of TNF mRNA [TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form; [TNF protein co-treated with bafilomycin A1] results in increased expression of SQSTM1 protein; resveratrol promotes the reaction [[TNF protein co-treated with bafilomycin A1] results in increased expression of MAP1LC3B protein alternative form] |
CTD |
PMID:16932910 PMID:24145604 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions increases expression |
ISO |
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CASP3 protein; bafilomycin A1 inhibits the reaction [[cobaltous chloride co-treated with TP53 gene mutant form] results in increased activity of CTSB protein] |
CTD |
PMID:23380477 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
multiple interactions |
EXP |
bafilomycin A1 affects the reaction [N-(1,3-benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide affects the reaction [Glucose affects the phosphorylation of ULK1 protein]] |
CTD |
PMID:29128638 |
|
NCBI chr12:45,851,710...45,877,966
Ensembl chr12:45,851,710...45,877,966
|
|
G |
Usp8 |
ubiquitin specific peptidase 8 |
multiple interactions |
ISO |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [bafilomycin A1 results in increased cleavage of PARP1 protein]; bafilomycin A1 promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:35022897 |
|
NCBI chr 3:113,962,136...114,009,683
Ensembl chr 3:113,962,164...114,009,666
|
|
G |
Vdac1 |
voltage-dependent anion channel 1 |
multiple interactions increases expression |
ISO |
Triiodothyronine promotes the reaction [bafilomycin A1 results in increased expression of VDAC1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640
|
|
G |
Vdr |
vitamin D receptor |
multiple interactions |
ISO |
[bafilomycin A1 co-treated with Vitamin D] results in increased expression of VDR protein; [Silicon Dioxide co-treated with Vitamin D co-treated with bafilomycin A1] results in increased expression of VDR protein |
CTD |
PMID:30698894 |
|
NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677
|
|
G |
Vim |
vimentin |
multiple interactions increases expression |
ISO |
bafilomycin A1 promotes the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased expression of VIM protein] bafilomycin A1 results in increased expression of VIM protein |
CTD |
PMID:32645460 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of ABCB1 mRNA; Chloroquine results in decreased expression of ABCB1 protein Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1 mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1 protein]; Chloroquine promotes the reaction [Cisplatin results in decreased expression of ABCB1 mRNA]; Chloroquine promotes the reaction [Cisplatin results in decreased expression of ABCB1 protein]; Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1 protein Chloroquine results in decreased expression of ABCB1A mRNA [Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein; Bortezomib promotes the reaction [Chloroquine results in decreased expression of ABCB1A mRNA]; Bortezomib promotes the reaction [Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of ABCB1A mRNA]; Chloroquine promotes the reaction [Bortezomib results in decreased expression of and results in increased nitrosation of ABCB1A protein]; Chloroquine results in decreased expression of and results in increased nitrosation of ABCB1A protein; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]] |
CTD |
PMID:25987058 PMID:27692344 PMID:30482226 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
ISO |
Chloroquine results in decreased expression of ABCC1 mRNA; Chloroquine results in decreased expression of ABCC1 protein |
CTD |
PMID:27692344 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
Chloroquine results in decreased expression of ABCC2 mRNA; Chloroquine results in decreased expression of ABCC2 protein |
CTD |
PMID:27692344 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
decreases expression |
ISO |
Chloroquine results in decreased expression of ABCG2 mRNA; Chloroquine results in decreased expression of ABCG2 protein |
CTD |
PMID:27692344 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Chloroquine promotes the reaction [ABL1 protein mutant form binds to BECN1 protein]; Chloroquine promotes the reaction [ABL1 protein mutant form binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of ACTA2 protein]] |
CTD |
PMID:35104487 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
Chloroquine affects the reaction [Cannabidiol results in decreased phosphorylation of AKT1 protein]; Chloroquine inhibits the reaction [formosanin C results in decreased phosphorylation of AKT1 protein] Chloroquine results in decreased phosphorylation of AKT1 protein Chloroquine inhibits the reaction [[Diethylnitrosamine co-treated with N-nitrosomorpholine] results in increased expression of and results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:24990399 PMID:27180204 PMID:32060308 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Akt1s1 |
AKT1 substrate 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr 1:95,333,186...95,339,678
Ensembl chr 1:95,332,898...95,339,677
|
|
G |
Aldh1b1 |
aldehyde dehydrogenase 1 family, member B1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of ALDH1B1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378
|
|
G |
Angptl8 |
angiopoietin-like 8 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [ANGPTL8 protein results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24262987 |
|
NCBI chr 8:20,376,462...20,378,488
Ensembl chr 8:20,376,462...20,378,490
|
|
G |
Apod |
apolipoprotein D |
affects localization |
ISO |
Chloroquine affects the localization of APOD protein |
CTD |
PMID:28182653 |
|
NCBI chr11:69,431,261...69,452,306
Ensembl chr11:69,431,260...69,452,305
|
|
G |
Apoe |
apolipoprotein E |
affects localization |
EXP |
Chloroquine affects the localization of APOE protein |
CTD |
PMID:8616629 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
affects expression increases expression affects localization multiple interactions |
EXP |
Chloroquine affects the expression of APP mRNA; Chloroquine affects the expression of APP protein Chloroquine results in increased expression of APP protein Chloroquine affects the localization of APP protein Chloroquine affects the localization of and affects the cleavage of APP protein |
CTD |
PMID:7715800 PMID:8616629 PMID:8787835 PMID:9690670 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Appl1 |
adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Lipopolysaccharides results in increased degradation of APPL1 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased degradation of APPL1 protein] |
CTD |
PMID:25780039 |
|
NCBI chr16:2,118,503...2,166,741
Ensembl chr16:2,121,255...2,166,692
|
|
G |
Aqp2 |
aquaporin 2 |
decreases degradation multiple interactions decreases expression |
ISO |
Chloroquine results in decreased degradation of AQP2 protein Chloroquine inhibits the reaction [AVP protein affects the localization of AQP2 protein] Chloroquine results in decreased expression of AQP2 protein |
CTD |
PMID:21734099 PMID:22791344 |
|
NCBI chr 7:130,711,433...130,716,468
Ensembl chr 7:130,711,413...130,716,468
|
|
G |
Aqp5 |
aquaporin 5 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Cyclic AMP results in decreased expression of AQP5 protein] |
CTD |
PMID:15536076 |
|
NCBI chr 7:130,722,675...130,726,207
Ensembl chr 7:130,721,748...130,726,209
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Riluzole results in increased degradation of and results in decreased expression of AR protein alternative form]; Chloroquine inhibits the reaction [Riluzole results in increased degradation of and results in decreased expression of AR protein] |
CTD |
PMID:30280407 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Arcn1 |
archain 1 |
affects localization |
ISO |
Chloroquine affects the localization of ARCN1 protein |
CTD |
PMID:29940786 |
|
NCBI chr 8:45,057,617...45,082,224
Ensembl chr 8:45,057,619...45,082,247
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of ASS1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions |
EXP |
Chloroquine promotes the reaction [cadmium acetate results in increased expression of ATF4 protein] |
CTD |
PMID:29870746 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions increases expression |
ISO EXP |
Chloroquine inhibits the reaction [hydroxyethyl methacrylate results in increased expression of ATG5 protein]; Chloroquine promotes the reaction [Arsenic Trioxide results in increased expression of ATG5 protein] Chloroquine results in increased expression of ATG5 protein Chloroquine inhibits the reaction [cadmium acetate results in increased expression of ATG5 protein] |
CTD |
PMID:28184909 PMID:29870746 PMID:30338810 |
|
NCBI chr20:47,798,222...47,889,216
Ensembl chr20:47,798,290...47,889,209
|
|
G |
Atm |
ATM serine/threonine kinase |
increases phosphorylation |
ISO |
Chloroquine results in increased phosphorylation of ATM protein |
CTD |
PMID:18089834 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
increases expression multiple interactions |
ISO EXP |
Chloroquine results in increased expression of ATP1A1 protein Chloroquine inhibits the reaction [Cadmium Chloride results in decreased expression of ATP1A1 protein] |
CTD |
PMID:10506578 PMID:26750564 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [AVP protein affects the localization of AQP2 protein]; Chloroquine inhibits the reaction [AVP protein affects the localization of SLC14A2 protein] |
CTD |
PMID:22791344 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO EXP |
BAX mutant form inhibits the reaction [Chloroquine results in increased activity of CASP3 protein]; Chloroquine promotes the reaction [triethylene glycol dimethacrylate results in increased expression of BAX protein] Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of BAX protein]]; Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of BAX protein]] Chloroquine affects the folding of and results in increased activity of BAX protein; Chloroquine inhibits the reaction [formosanin C results in increased expression of BAX protein]; Chloroquine promotes the reaction [dactolisib affects the folding of and results in increased activity of BAX protein]; dactolisib promotes the reaction [Chloroquine affects the folding of and results in increased activity of BAX protein] |
CTD |
PMID:11589424 PMID:23151917 PMID:27180204 PMID:28713934 PMID:33684387 PMID:35104487 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression |
ISO |
Chloroquine results in increased expression of BBC3 mRNA |
CTD |
PMID:31310755 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO EXP |
Chloroquine inhibits the reaction [formosanin C results in decreased expression of BCL2 protein] Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in decreased expression of BCL2 protein]]; Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of BCL2 protein]] |
CTD |
PMID:27180204 PMID:28713934 PMID:35104487 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
ISO |
BCL2L1 mutant form promotes the reaction [Chloroquine results in increased activity of CASP3 protein] Chloroquine results in increased expression of BCL2L1 mRNA |
CTD |
PMID:11589424 PMID:31310755 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Becn1 |
beclin 1 |
decreases expression multiple interactions |
ISO EXP |
Chloroquine results in decreased expression of BECN1 mRNA; Chloroquine results in decreased expression of BECN1 protein Chloroquine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of BECN1 protein] Chloroquine inhibits the reaction [cadmium acetate results in increased expression of BECN1 protein]; Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of BECN1 protein]] Carboplatin promotes the reaction [Chloroquine results in decreased expression of BECN1 protein]; Chloroquine inhibits the reaction [Cannabidiol results in increased expression of BECN1 protein]; Chloroquine inhibits the reaction [Cisplatin results in increased expression of BECN1 protein]; Chloroquine inhibits the reaction [hydroxyethyl methacrylate results in increased expression of BECN1 protein]; Chloroquine promotes the reaction [ABL1 protein mutant form binds to BECN1 protein]; Chloroquine promotes the reaction [Carboplatin results in decreased expression of BECN1 protein]; Chloroquine promotes the reaction [XPO1 protein binds to BECN1 protein] |
CTD |
PMID:25987058 PMID:27692344 PMID:28184909 PMID:29870746 PMID:31862506 PMID:32060308 PMID:33070465 PMID:35104487 More...
|
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of BGLAP mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [sunitinib results in decreased expression of BIRC5 protein] Chloroquine promotes the reaction [Immunologic Factors results in decreased expression of BIRC5 protein] |
CTD |
PMID:24751611 PMID:27823620 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions increases expression |
ISO |
vistusertib inhibits the reaction [Chloroquine results in increased expression of BNIP3 protein] |
CTD |
PMID:26853465 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Btrc |
beta-transducin repeat containing E3 ubiquitin protein ligase |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax co-treated with hydroquinone] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of BTRC protein] |
CTD |
PMID:35561756 |
|
NCBI chr 1:244,210,299...244,380,126
Ensembl chr 1:244,210,314...244,376,721
|
|
G |
Calr |
calreticulin |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of CALR mRNA [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Chloroquine results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Chloroquine results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein; [Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Chloroquine results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Chloroquine results in increased expression of CALR mRNA]; Chloroquine promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Chloroquine results in increased expression of and affects the localization of CALR protein; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [Chloroquine affects the localization of CALR protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; Doxorubicin promotes the reaction [Chloroquine affects the localization of CALR protein] [Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]] |
CTD |
PMID:30482226 |
|
NCBI chr19:23,308,525...23,313,420
Ensembl chr19:23,308,351...23,313,414
|
|
G |
Casp12 |
caspase 12 |
multiple interactions |
EXP |
Chloroquine promotes the reaction [cadmium acetate results in increased expression of CASP12 protein] |
CTD |
PMID:29870746 |
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases expression increases activity |
ISO EXP |
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Chloroquine results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased cleavage of CASP3 protein]; [aloxistatin co-treated with pepstatin] inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein; [Chloroquine co-treated with vandetanib] results in increased activity of CASP3 protein; [vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CA 074 methyl ester inhibits the reaction [[capivasertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; CA 074 methyl ester inhibits the reaction [[vistusertib co-treated with Chloroquine] results in increased activity of CASP3 protein]; Chloroquine inhibits the reaction [alpinetin inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]]; Chloroquine inhibits the reaction [betulin results in increased cleavage of CASP3 protein]; Chloroquine inhibits the reaction [Biological Products results in increased cleavage of CASP3 protein]; Chloroquine inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein]; Chloroquine inhibits the reaction [Cannabidiol results in increased cleavage of CASP3 protein]; Chloroquine inhibits the reaction [formosanin C results in increased expression of and results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [Amiodarone results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [Arsenic Trioxide results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [Biological Products results in increased expression of and results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [Cisplatin results in increased expression of CASP3 protein]; Chloroquine promotes the reaction [dactolisib results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]; Chloroquine promotes the reaction [usnic acid results in increased activity of CASP3 protein]; dactolisib promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Chloroquine results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein]; NDRG1 protein affects the reaction [Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]]; NDRG1 protein affects the reaction [Chloroquine results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein] Chloroquine results in increased expression of CASP3 protein Chloroquine inhibits the reaction [3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased activity of CASP3 protein]]; Chloroquine inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]]; Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of CASP3 protein]]; Chloroquine promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein] Chloroquine results in increased activity of CASP3 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [Chloroquine results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased cleavage of CASP3 protein]; [Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein; [Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein; [Rotenone co-treated with Chloroquine] results in increased cleavage of CASP3 protein; BAX mutant form inhibits the reaction [Chloroquine results in increased activity of CASP3 protein]; BCL2L1 mutant form promotes the reaction [Chloroquine results in increased activity of CASP3 protein]; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Chloroquine inhibits the reaction [Cadmium results in increased cleavage of CASP3 protein]; Chloroquine inhibits the reaction [trichostatin A inhibits the reaction [Cisplatin results in increased expression of CASP3 protein modified form]]; Chloroquine promotes the reaction [Cisplatin results in increased expression of CASP3 protein modified form]; Chloroquine promotes the reaction [Sunitinib results in increased activity of CASP3 protein]; Chloroquine promotes the reaction [triethylene glycol dimethacrylate results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased cleavage of CASP3 protein]; TRP53 mutant form inhibits the reaction [Chloroquine results in increased activity of CASP3 protein] |
CTD |
PMID:11589424 PMID:23151917 PMID:23799852 PMID:24751611 PMID:25078063 PMID:25266202 PMID:25987058 PMID:26847702 PMID:26853465 PMID:27180204 PMID:28219700 PMID:28906492 PMID:29111403 PMID:29476062 PMID:30338810 PMID:30465897 PMID:30482226 PMID:30985881 PMID:31332898 PMID:31676321 PMID:32060308 PMID:32190974 PMID:32651653 PMID:33684387 PMID:34374793 PMID:35104487 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [usnic acid results in increased activity of CASP7 protein] |
CTD |
PMID:25078063 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases cleavage multiple interactions |
ISO |
Chloroquine results in increased cleavage of CASP8 protein Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of CASP8 protein] Chloroquine inhibits the reaction [Cadmium results in increased cleavage of CASP8 protein] |
CTD |
PMID:27692344 PMID:28906492 PMID:29111403 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases cleavage |
ISO |
[Chloroquine co-treated with vandetanib] results in increased activity of CASP9 protein; Chloroquine inhibits the reaction [Cannabidiol results in increased cleavage of CASP9 protein]; Chloroquine inhibits the reaction [hydroxyethyl methacrylate results in increased expression of CASP9 mRNA]; Chloroquine promotes the reaction [dactolisib results in increased cleavage of CASP9 protein]; Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of CASP9 protein]; dactolisib promotes the reaction [Chloroquine results in increased cleavage of CASP9 protein] |
CTD |
PMID:23151917 PMID:23799852 PMID:28184909 PMID:28906492 PMID:32060308 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Casr |
calcium-sensing receptor |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of CASR mRNA]; Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of CASR protein] |
CTD |
PMID:32956540 |
|
NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811
|
|
G |
Cat |
catalase |
decreases activity multiple interactions decreases expression |
EXP ISO |
Chloroquine results in decreased activity of CAT protein Chloroquine promotes the reaction [sunitinib results in increased activity of CAT protein]; Quercetin inhibits the reaction [Chloroquine results in decreased activity of CAT protein]; Quercetin inhibits the reaction [Chloroquine results in decreased expression of CAT mRNA] Curcumin inhibits the reaction [Chloroquine results in decreased activity of CAT protein]; tetrahydrocurcumin inhibits the reaction [Chloroquine results in decreased activity of CAT protein] Chloroquine results in decreased expression of CAT protein |
CTD |
PMID:15526909 PMID:17076682 PMID:23607047 PMID:24751611 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL1 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:67,128,331...67,131,109
Ensembl chr10:67,128,331...67,131,159
|
|
G |
Ccl11 |
C-C motif chemokine ligand 11 |
multiple interactions decreases secretion |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL11 protein] Chloroquine results in decreased secretion of CCL11 protein |
CTD |
PMID:22341560 PMID:29772762 |
|
NCBI chr10:67,028,328...67,032,929
Ensembl chr10:67,028,328...67,032,926
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression decreases secretion multiple interactions |
ISO |
Chloroquine results in increased expression of CCL2 mRNA Chloroquine results in decreased secretion of CCL2 protein Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL2 protein] Acetylcysteine inhibits the reaction [Chloroquine results in increased expression of CCL2 mRNA]; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Chloroquine results in increased expression of CCL2 mRNA]; Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in decreased expression of MCP1 protein]; diphenyliodonium inhibits the reaction [Chloroquine results in increased expression of CCL2 mRNA]; Tosylphenylalanyl Chloromethyl Ketone inhibits the reaction [Chloroquine results in increased expression of CCL2 mRNA] |
CTD |
PMID:15139008 PMID:22341560 PMID:29772762 PMID:35561756 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl25 |
C-C motif chemokine ligand 25 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL25 protein] |
CTD |
PMID:22341560 |
|
NCBI chr12:2,707,398...2,716,571
Ensembl chr12:2,707,398...2,716,554
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CCL5 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccn1 |
cellular communication network factor 1 |
increases expression multiple interactions |
EXP ISO |
Chloroquine results in increased expression of CCN1 mRNA Chloroquine inhibits the reaction [pterostilbene inhibits the reaction [Ethanol results in increased expression of CCN1 protein]] |
CTD |
PMID:19393257 PMID:34405320 |
|
NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484
|
|
G |
Cd274 |
CD274 molecule |
decreases expression |
ISO |
Chloroquine results in decreased expression of CD274 protein |
CTD |
PMID:27692344 |
|
NCBI chr 1:227,116,627...227,137,379
Ensembl chr 1:227,116,649...227,134,450
|
|
G |
Cd34 |
CD34 molecule |
multiple interactions |
ISO |
Chloroquine promotes the reaction [sunitinib results in decreased expression of CD34 protein] |
CTD |
PMID:24751611 |
|
NCBI chr13:106,480,074...106,499,462
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; Chloroquine inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein] |
CTD |
PMID:30053495 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdh2 |
cadherin 2 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Dibutyl Phthalate results in increased expression of CDH2 mRNA]; Chloroquine inhibits the reaction [Dibutyl Phthalate results in increased expression of CDH2 protein] |
CTD |
PMID:30053495 |
|
NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases activity multiple interactions increases expression |
ISO |
Chloroquine results in increased activity of CDKN1A [Chloroquine co-treated with flavokawain B] results in decreased expression of CDKN1A protein; Chloroquine inhibits the reaction [Doxorubicin results in increased expression of CDKN1A protein] Chloroquine results in increased expression of CDKN1A protein |
CTD |
PMID:12243503 PMID:18089834 PMID:22927544 PMID:30025493 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of CEBPB protein alternative form 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of CEBPB protein alternative form]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CALR mRNA]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Chloroquine results in increased expression of and affects the localization of CALR protein]; [CEBPB protein alternative form results in increased susceptibility to Doxorubicin] promotes the reaction [Chloroquine results in increased expression of CALR mRNA]; [Chloroquine co-treated with Bortezomib] promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR mRNA]; CEBPB protein alternative form promotes the reaction [Chloroquine results in increased expression of and affects the localization of CALR protein]; CEBPB protein alternative form promotes the reaction [Chloroquine results in increased expression of CALR mRNA]; Chloroquine promotes the reaction [CEBPB protein alternative form binds to CALR promoter]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [Chloroquine results in increased expression of CEBPB protein alternative form] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of CEBPB protein alternative form]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of CEBPB protein alternative form]; [Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CEBPB protein alternative form]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in decreased expression of ABCB1A protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of CALR protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]]; Doxorubicin promotes the reaction [Chloroquine results in increased expression of CEBPB protein alternative form] |
CTD |
PMID:30482226 |
|
NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
decreases expression |
ISO |
Chloroquine results in decreased expression of CHUK protein |
CTD |
PMID:26116531 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cip2a |
cellular inhibitor of PP2A |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [temsirolimus results in decreased expression of CIP2A protein] |
CTD |
PMID:24493623 |
|
NCBI chr11:51,792,143...51,823,016
Ensembl chr11:51,795,024...51,822,938
|
|
G |
Cldn1 |
claudin 1 |
increases expression |
ISO |
Chloroquine results in increased expression of CLDN1 mRNA |
CTD |
PMID:25752684 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Cldn2 |
claudin 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [caffeic acid phenethyl ester results in decreased expression of CLDN2 protein] |
CTD |
PMID:29597147 |
|
NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838
|
|
G |
Clu |
clusterin |
affects localization |
EXP |
Chloroquine affects the localization of CLU protein |
CTD |
PMID:8616629 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Coq6 |
coenzyme Q6 monooxygenase |
decreases expression |
EXP |
Chloroquine results in decreased expression of COQ6 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 6:104,007,814...104,019,888
Ensembl chr 6:104,007,872...104,024,657
|
|
G |
Cox4i1 |
cytochrome c oxidase subunit 4i1 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of COX4I1 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921
|
|
G |
Cs |
citrate synthase |
multiple interactions |
ISO |
Chloroquine affects the reaction [triethylene glycol dimethacrylate affects the activity of CS protein] |
CTD |
PMID:33684387 |
|
NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Dibutyl Phthalate results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:30053495 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Ctrb1 |
chymotrypsinogen B1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of CTRB1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr19:39,652,931...39,657,666
Ensembl chr19:39,652,933...39,657,688
|
|
G |
Ctsa |
cathepsin A |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSA protein |
CTD |
PMID:30821613 |
|
NCBI chr 3:153,569,106...153,574,983
Ensembl chr 3:153,568,381...153,576,215
|
|
G |
Ctsb |
cathepsin B |
increases expression decreases activity multiple interactions |
EXP ISO |
Chloroquine results in increased expression of CTSB protein Chloroquine results in decreased activity of CTSB protein [Chloroquine co-treated with dactolisib] affects the localization of CTSB protein; [quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSB protein; Chloroquine inhibits the reaction [Arsenic Trioxide results in increased activity of CTSB protein] |
CTD |
PMID:2759144 PMID:23151917 PMID:30338810 PMID:30821613 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Ctsd |
cathepsin D |
affects localization multiple interactions increases expression |
EXP ISO |
Chloroquine affects the localization of CTSD protein [quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of CTSD protein Chloroquine results in increased expression of CTSD protein |
CTD |
PMID:2759144 PMID:7715800 PMID:30821613 |
|
NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488
|
|
G |
Ctsl |
cathepsin L |
increases expression |
EXP |
Chloroquine results in increased expression of CTSL protein |
CTD |
PMID:2759144 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [CpG ODN 2216 results in increased expression of CXCL10 protein]; Chloroquine inhibits the reaction [gardiquimod results in increased expression of CXCL10 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of CXCL10 protein] |
CTD |
PMID:26682054 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl12 |
C-X-C motif chemokine ligand 12 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL12 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:150,388,326...150,401,173
Ensembl chr 4:150,388,325...150,401,168
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of CXCL9 protein] |
CTD |
PMID:22341560 |
|
NCBI chr14:15,722,868...15,727,779
Ensembl chr14:15,722,908...15,728,435
|
|
G |
Cyp11a1 |
cytochrome P450, family 11, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of CYP11A1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 8:58,422,807...58,434,342
Ensembl chr 8:58,404,669...58,434,338
|
|
G |
Cyp17a1 |
cytochrome P450, family 17, subfamily a, polypeptide 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of CYP17A1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [CYP1A2 protein results in increased metabolism of Tacrine] |
CTD |
PMID:7946932 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
affects metabolic processing multiple interactions increases metabolic processing |
ISO |
CYP2C8 polymorphism affects the metabolism of Chloroquine; CYP2C8 protein affects the metabolism of Chloroquine [CYP2C8 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine; Quercetin inhibits the reaction [[CYP2C8 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine] |
CTD |
PMID:12756207 PMID:12920490 PMID:12967198 PMID:17286541 PMID:19560616 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
affects metabolic processing multiple interactions decreases activity |
ISO |
CYP2D6 protein affects the metabolism of Chloroquine [CYP2D6 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine Chloroquine results in decreased activity of CYP2D6 protein |
CTD |
PMID:12756207 PMID:12920490 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases activity multiple interactions affects metabolic processing |
ISO |
Chloroquine results in decreased activity of CYP3A4 protein [CYP3A4 protein results in increased metabolism of Chloroquine] which results in increased abundance of desethylchloroquine CYP3A4 protein affects the metabolism of Chloroquine |
CTD |
PMID:11124226 PMID:12756207 PMID:12920490 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [CYP7A1 protein results in increased expression of MAP1LC3B protein modified form]; CYP7A1 mRNA promotes the reaction [Chloroquine results in increased expression of MAP1LC3B protein modified form] |
CTD |
PMID:28275691 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
EXP ISO |
Chloroquine promotes the reaction [cadmium acetate results in increased expression of DDIT3 protein]; Chloroquine promotes the reaction [Cadmium results in increased expression of DDIT3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] affects the localization of CALR protein]; DDIT3 protein affects the reaction [[Chloroquine co-treated with Bortezomib] results in increased cleavage of CASP3 protein]; DDIT3 protein affects the reaction [Chloroquine affects the localization of CALR protein]; DDIT3 protein affects the reaction [Chloroquine results in increased cleavage of CASP3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [Chloroquine results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased expression of DDIT3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of DDIT3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein; [Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of DDIT3 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]]; Doxorubicin promotes the reaction [Chloroquine results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of DDIT3 protein]; Nitroprusside inhibits the reaction [Chloroquine results in increased expression of DDIT3 protein] |
CTD |
PMID:27658547 PMID:29870746 PMID:30482226 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Ddx3x |
DEAD-box helicase 3, X-linked |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of DDX3X protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:9,479,532...9,493,455
Ensembl chr X:9,479,532...9,493,168
|
|
G |
Eea1 |
early endosome antigen 1 |
affects localization |
ISO |
Chloroquine affects the localization of EEA1 protein |
CTD |
PMID:29940786 |
|
NCBI chr 7:30,554,686...30,722,186
Ensembl chr 7:30,554,552...30,718,487
|
|
G |
Egf |
epidermal growth factor |
multiple interactions |
ISO EXP |
Chloroquine inhibits the reaction [EGF protein results in decreased expression of EGFR protein] Chloroquine inhibits the reaction [EGF protein results in increased expression of RHEB protein]; Chloroquine inhibits the reaction [EGF protein results in increased phosphorylation of AKT1S1 protein]; Chloroquine inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein]; Chloroquine inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein]; Chloroquine promotes the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] |
CTD |
PMID:20332299 PMID:22689575 |
|
NCBI chr 2:218,219,408...218,302,370
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions decreases expression |
ISO EXP |
Chloroquine inhibits the reaction [EGF protein results in decreased expression of EGFR protein]; Chloroquine inhibits the reaction [MUC1 affects the expression of EGFR protein]; Chloroquine inhibits the reaction [sulindac sulfide results in decreased expression of EGFR protein]; Chloroquine inhibits the reaction [sulindac sulfone results in decreased expression of EGFR protein]; Chloroquine inhibits the reaction [tephrosin results in increased degradation of EGFR protein] Chloroquine promotes the reaction [EGF protein results in increased expression of and results in increased phosphorylation of EGFR protein] Chloroquine results in decreased expression of EGFR protein |
CTD |
PMID:20056314 PMID:20332299 PMID:22457794 PMID:22689575 |
|
NCBI chr14:91,176,931...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4A1 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein] |
CTD |
PMID:30821613 |
|
NCBI chr10:54,384,345...54,389,853
Ensembl chr10:54,384,347...54,389,858
|
|
G |
Eif4ebp1 |
eukaryotic translation initiation factor 4E binding protein 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [EGF protein results in increased phosphorylation of EIF4EBP1 protein] |
CTD |
PMID:22689575 |
|
NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984
|
|
G |
Eif4h |
eukaryotic translation initiation factor 4H |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein; Chloroquine inhibits the reaction [[quizartinib co-treated with spautin-1] results in increased degradation of EIF4H protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein] |
CTD |
PMID:30821613 |
|
NCBI chr12:22,083,155...22,099,876
Ensembl chr12:22,082,835...22,099,876
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Sirolimus results in increased expression of ENO2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of ERBB2 protein Chloroquine inhibits the reaction [tephrosin results in increased degradation of ERBB2 protein] |
CTD |
PMID:20056314 PMID:20332299 |
|
NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078
|
|
G |
Erbb3 |
erb-b2 receptor tyrosine kinase 3 |
decreases expression |
ISO |
Chloroquine results in decreased expression of ERBB3 protein |
CTD |
PMID:20332299 |
|
NCBI chr 7:994,549...1,015,876
Ensembl chr 7:996,225...1,015,525
|
|
G |
Ergic3 |
ERGIC and golgi 3 |
multiple interactions |
ISO |
ERGIC3 protein promotes the reaction [Chloroquine results in increased expression of SQSTM1 protein] |
CTD |
PMID:27588471 |
|
NCBI chr 3:144,525,059...144,534,813
Ensembl chr 3:144,525,092...144,534,813
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
EXP |
Chloroquine results in decreased expression of FADS2 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Faslg |
Fas ligand |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of FASL protein] |
CTD |
PMID:22341560 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fbxo32 |
F-box protein 32 |
affects expression |
EXP |
Chloroquine affects the expression of FBXO32 mRNA |
CTD |
PMID:19296457 |
|
NCBI chr 7:89,731,626...89,764,761
Ensembl chr 7:89,730,232...89,765,436
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in decreased expression of FGF1 mRNA]] |
CTD |
PMID:31332898 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fmn1 |
formin 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of FMN1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 3:100,101,103...100,485,652
Ensembl chr 3:100,134,549...100,479,220
|
|
G |
Foxp3 |
forkhead box P3 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [dorsomorphin results in decreased expression of FOXP3 mRNA]; Chloroquine inhibits the reaction [dorsomorphin results in decreased expression of FOXP3 protein] |
CTD |
PMID:31900833 |
|
NCBI chr X:14,908,494...14,924,994
Ensembl chr X:14,908,494...14,923,838
|
|
G |
Fth1 |
ferritin heavy chain 1 |
multiple interactions increases expression |
ISO EXP |
Chloroquine inhibits the reaction [Artesunate results in decreased expression of FTH1 mRNA] Chloroquine promotes the reaction [erastin results in increased expression of FTH1 protein] Chloroquine results in increased expression of FTH1 mRNA |
CTD |
PMID:30551460 PMID:32937103 |
|
NCBI chr 1:206,627,142...206,629,430
Ensembl chr 1:206,627,103...206,725,424
|
|
G |
Fundc1 |
FUN14 domain containing 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Rotenone results in decreased expression of FUNDC1 protein] |
CTD |
PMID:32001317 |
|
NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284
|
|
G |
Gal3st1 |
galactose-3-O-sulfotransferase 1 |
multiple interactions |
ISO |
GAL3ST1 protein affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:23880069 |
|
NCBI chr14:78,868,049...78,886,402
Ensembl chr14:78,870,793...78,886,388
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
multiple interactions |
ISO EXP |
Chloroquine inhibits the reaction [LAMB1 protein affects the localization of GJA1 protein] Chloroquine inhibits the reaction [DDT results in increased degradation of GJA1 protein modified form]; Chloroquine inhibits the reaction [Hexachlorocyclohexane results in increased degradation of GJA1 protein modified form]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [Glucose results in increased expression of GJA1 protein]]; Chloroquine promotes the reaction [Glucose results in increased expression of GJA1 protein] |
CTD |
PMID:8824497 PMID:22150760 PMID:28713934 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gjb2 |
gap junction protein, beta 2 |
decreases expression |
EXP |
Chloroquine results in decreased expression of GJB2 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr15:31,260,390...31,278,222
Ensembl chr15:31,260,357...31,278,177
|
|
G |
Glb1 |
galactosidase, beta 1 |
multiple interactions |
ISO |
[Chloroquine co-treated with flavokawain B] results in decreased expression of GLB1 protein |
CTD |
PMID:30025493 |
|
NCBI chr 8:114,085,508...114,158,127
Ensembl chr 8:114,085,508...114,158,127
|
|
G |
Glp1r |
glucagon-like peptide 1 receptor |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Oleic Acid results in increased degradation of and results in decreased expression of GLP1R protein] |
CTD |
PMID:22925809 |
|
NCBI chr20:8,972,004...9,010,241
Ensembl chr20:8,972,004...9,010,241
|
|
G |
Golga2 |
golgin A2 |
affects localization |
ISO |
Chloroquine affects the localization of GOLGA2 protein |
CTD |
PMID:29940786 |
|
NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279
|
|
G |
Gpnmb |
glycoprotein nmb |
increases expression |
EXP |
Chloroquine results in increased expression of GPNMB mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367
|
|
G |
Gpr182 |
G protein-coupled receptor 182 |
decreases expression |
EXP |
Chloroquine results in decreased expression of GPR182 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 7:63,585,997...63,589,088
Ensembl chr 7:63,578,750...63,589,210
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [coenzyme Q10 inhibits the reaction [Acetaminophen results in increased activity of GPT protein]]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased activity of GPT protein]]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased activity of GPT protein]; Chloroquine promotes the reaction [Acetaminophen results in increased activity of GPT protein] |
CTD |
PMID:26498332 PMID:33271250 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions decreases expression |
ISO |
Chloroquine inhibits the reaction [Cisplatin results in decreased expression of GPX4 protein]; Quercetin inhibits the reaction [Chloroquine results in decreased expression of GPX4 mRNA] |
CTD |
PMID:23607047 PMID:34302894 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Grin2b |
glutamate ionotropic receptor NMDA type subunit 2B |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Nanotubes, Carbon results in decreased expression of GRIN2B] |
CTD |
PMID:26327526 |
|
NCBI chr 4:168,580,824...169,044,110
Ensembl chr 4:168,599,546...169,042,279
|
|
G |
Gsdmd |
gasdermin D |
multiple interactions |
ISO |
Chloroquine promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of and results in increased cleavage of GSDMD protein] |
CTD |
PMID:34920032 |
|
NCBI chr 7:107,542,242...107,547,052
Ensembl chr 7:107,542,083...107,547,055
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions decreases activity decreases expression |
ISO |
Quercetin inhibits the reaction [Chloroquine results in decreased activity of GSR protein]; Quercetin inhibits the reaction [Chloroquine results in decreased expression of GSR mRNA] |
CTD |
PMID:23607047 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hbg1 |
hemoglobin subunit gamma 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of HBG1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 1:158,271,993...158,273,371
Ensembl chr 1:158,271,873...158,273,425
|
|
G |
Hdac6 |
histone deacetylase 6 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in increased expression of HDAC6 protein]] |
CTD |
PMID:35104487 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
decreases expression |
ISO |
Chloroquine results in decreased expression of HIF1A protein |
CTD |
PMID:32060308 |
|
NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261
|
|
G |
Hk2 |
hexokinase 2 |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein] |
CTD |
PMID:30821613 |
|
NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530
|
|
G |
Hmbs |
hydroxymethylbilane synthase |
increases response to substance |
ISO |
HMBS mutant form results in increased susceptibility to Chloroquine |
CTD |
PMID:8772850 |
|
NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [CPG-oligonucleotide results in increased expression of HSPA1B protein] |
CTD |
PMID:17046822 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Chloroquine promotes the reaction [cadmium acetate results in increased expression of HSPA5 protein] |
CTD |
PMID:29870746 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HSPA8 protein alternative form |
CTD |
PMID:30821613 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]] |
CTD |
PMID:24145604 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifnb1 |
interferon beta 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 mRNA]; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 mRNA]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 protein]] |
CTD |
PMID:28134560 |
|
NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IFNG mRNA [Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IFNG protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of IFNG protein]] |
CTD |
PMID:22341560 PMID:29594315 PMID:30482226 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
decreases expression |
ISO |
Chloroquine results in decreased expression of IKBKB protein |
CTD |
PMID:26116531 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
decreases expression |
ISO |
Chloroquine results in decreased expression of IKBKG protein |
CTD |
PMID:26116531 |
|
NCBI chr X:152,216,485...152,241,476
Ensembl chr X:152,216,596...152,239,499
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL10 protein] |
CTD |
PMID:22341560 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il13 |
interleukin 13 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL13 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il17a |
interleukin 17A |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL17A protein] |
CTD |
PMID:22341560 |
|
NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889
|
|
G |
Il18 |
interleukin 18 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of IL18 protein] |
CTD |
PMID:34920032 |
|
NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887
|
|
G |
Il1a |
interleukin 1 alpha |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of IL1A Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1A protein] |
CTD |
PMID:15139008 PMID:22341560 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
increases expression decreases expression multiple interactions |
ISO |
Chloroquine results in increased expression of IL1B Chloroquine results in decreased expression of IL1B mRNA Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL1B protein]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B protein]]; Chloroquine inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B mRNA]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL1B protein] Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Chloroquine inhibits the reaction [Uric Acid results in increased secretion of IL1B protein]; Chloroquine promotes the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with sodium arsenite] results in increased expression of IL1B protein] |
CTD |
PMID:15139008 PMID:21051542 PMID:22341560 PMID:26498332 PMID:29594315 PMID:31648047 PMID:34920032 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of IL2 mRNA; Chloroquine results in decreased expression of IL2 protein Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL2 protein] [Chloroquine co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA |
CTD |
PMID:7554381 PMID:22341560 PMID:29594315 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il3 |
interleukin 3 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL3 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:38,405,716...38,408,066
Ensembl chr10:38,405,716...38,408,066
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL4 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
decreases expression decreases secretion multiple interactions increases expression |
ISO EXP |
Chloroquine results in decreased expression of IL6 protein Chloroquine results in decreased secretion of IL6 protein Chloroquine inhibits the reaction [3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased secretion of IL6 protein]] Chloroquine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]] [Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Bortezomib inhibits the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased secretion of IL6 protein]; Chloroquine inhibits the reaction [CPG-oligonucleotide results in increased secretion of IL6 protein]; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of IL6 protein]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL6 protein]]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL6 mRNA]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of IL6 protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]] Chloroquine results in increased expression of IL6 |
CTD |
PMID:9002011 PMID:9799232 PMID:10638776 PMID:15139008 PMID:22341560 PMID:26498332 PMID:28134560 PMID:29772762 PMID:31332898 PMID:31648047 More...
|
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of IRF3 protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased degradation of IRF3 protein]; Chloroquine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRF3 protein]; Chloroquine inhibits the reaction [Poly I-C results in increased phosphorylation of IRF3 protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of IRF3 protein]] |
CTD |
PMID:22341560 PMID:25780039 PMID:28134560 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
[benzyloxycarbonyl-valyl-alanyl-aspartic acid analog co-treated with Chloroquine] inhibits the reaction [Tretinoin affects the localization of ITGAM protein]; Chloroquine inhibits the reaction [Tretinoin affects the localization of ITGAM protein] |
CTD |
PMID:29743969 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Jak2 |
Janus kinase 2 |
decreases phosphorylation |
ISO |
chloroquine co-treated with anlotinib decreases phosphorylation of JAK2 protein in lung epithelium |
RGD |
PMID:30755242 |
RGD:149735343 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Lamb1 |
laminin subunit beta 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [LAMB1 protein affects the localization of GJA1 protein] |
CTD |
PMID:22150760 |
|
NCBI chr 6:47,835,492...47,902,585
Ensembl chr 6:47,835,525...47,902,585
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein; [quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein alternative form; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of DDX3X protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4A1 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of EIF4H protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of HK2 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of LAMP2 protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein] |
CTD |
PMID:30821613 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Lat2 |
linker for activation of T cells family, member 2 |
increases response to substance |
ISO |
LAT2 protein results in increased susceptibility to Chloroquine |
CTD |
PMID:32587277 |
|
NCBI chr12:22,104,163...22,118,294
Ensembl chr12:22,104,219...22,118,288
|
|
G |
Lcn2 |
lipocalin 2 |
increases expression |
EXP |
Chloroquine results in increased expression of LCN2 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions |
ISO |
Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]] |
CTD |
PMID:30950489 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of LEP protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lepr |
leptin receptor |
increases expression |
ISO |
Chloroquine results in increased expression of LEPR protein |
CTD |
PMID:31199479 |
|
NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908
|
|
G |
Ltb |
lymphotoxin beta |
increases expression |
ISO |
Chloroquine results in increased expression of LTB |
CTD |
PMID:15139008 |
|
NCBI chr20:3,627,536...3,629,381
Ensembl chr20:3,627,537...3,629,381
|
|
G |
M6pr |
mannose-6-phosphate receptor, cation dependent |
affects expression affects localization |
EXP ISO |
Chloroquine affects the expression of M6PR mRNA Chloroquine affects the localization of M6PR protein |
CTD |
PMID:15712280 PMID:29940786 |
|
NCBI chr 4:155,501,080...155,510,219
Ensembl chr 4:155,500,921...155,510,216
|
|
G |
Map1lc3a |
microtubule-associated protein 1 light chain 3 alpha |
increases expression |
ISO |
Chloroquine results in increased expression of MAP1LC3A protein; Chloroquine results in increased expression of MAP1LC3A protein modified form |
CTD |
PMID:30280407 PMID:30871063 |
|
NCBI chr 3:143,783,024...143,784,670
Ensembl chr 3:143,783,024...143,784,670
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions increases expression affects localization increases cleavage increases lipidation decreases degradation |
ISO EXP |
[Ethanol co-treated with Chloroquine] results in increased lipidation of MAP1LC3B protein; Chloroquine inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Chloroquine promotes the reaction [[Cadmium Chloride results in increased abundance of Cadmium] which results in increased lipidation of MAP1LC3B protein]; MJN110 affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein] Chloroquine results in increased expression of MAP1LC3B protein; Chloroquine results in increased expression of MAP1LC3B protein modified form Chloroquine affects the localization of MAP1LC3B protein Chloroquine results in increased cleavage of MAP1LC3B protein Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Cisplatin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [erastin results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [trichostatin A results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [Vorinostat results in increased expression of MAP1LC3B protein modified form] Chloroquine results in decreased degradation of MAP1LC3B protein modified form Chloroquine results in increased expression of MAP1LC3B mRNA; Chloroquine results in increased expression of MAP1LC3B protein; Chloroquine results in increased expression of MAP1LC3B protein modified form [Chloroquine co-treated with flavokawain B] results in increased expression of MAP1LC3B protein modified form; [Chloroquine co-treated with TNF protein] results in increased expression of MAP1LC3B protein alternative form; bafilomycin A1 inhibits the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; Chloroquine affects the reaction [dorsomorphin results in increased lipidation of MAP1LC3B protein]; Chloroquine affects the reaction [NDRG1 protein affects the lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [4-(6-bromo-1,3-benzodioxol-5-yl)-3a,4,5,9b-3H-cyclopenta(c)quinoline affects the localization of MAP1LC3B protein]; Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [[Simvastatin co-treated with Metformin] results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Chloroquine promotes the reaction [Arsenic Trioxide results in increased expression of MAP1LC3B protein]; Chloroquine promotes the reaction [CYP7A1 protein results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [Ethanol results in increased expression of MAP1LC3B protein]; Chloroquine promotes the reaction [flavokawain B results in increased expression of MAP1LC3B protein modified form]; Chloroquine promotes the reaction [fosbretabulin results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [olaparib promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [sepantronium results in increased lipidation of MAP1LC3B protein]; Chloroquine promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]; Chloroquine results in increased expression of and results in increased lipidation of MAP1LC3B protein; Chloroquine results in increased lipidation of and results in increased cleavage of MAP1LC3B protein; cryptotanshinone promotes the reaction [Chloroquine results in increased expression of MAP1LC3B protein]; CYP7A1 mRNA promotes the reaction [Chloroquine results in increased expression of MAP1LC3B protein modified form]; GAL3ST1 protein affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; Hydrogen Peroxide inhibits the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; NDRG1 protein affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; NOD2 protein affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; olaparib promotes the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; olaparib promotes the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; Paraquat inhibits the reaction [Chloroquine results in increased expression of MAP1LC3B protein modified form]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]]; TNF protein promotes the reaction [Chloroquine results in increased expression of and results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:17643062 PMID:23880069 PMID:24095927 PMID:24145604 PMID:24161432 PMID:24492484 PMID:25412314 PMID:25884947 PMID:26409479 PMID:28275691 PMID:28600121 PMID:28722353 PMID:28906492 PMID:29248574 PMID:29476062 PMID:30025493 PMID:30208301 PMID:30237538 PMID:30301768 PMID:30338810 PMID:31310755 PMID:31586597 PMID:31648047 PMID:31837377 PMID:31862506 PMID:31900833 PMID:32861759 PMID:32937103 PMID:33609687 PMID:34826546 PMID:35104487 More...
|
|
NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Sirolimus results in increased expression of MAP2 protein] |
CTD |
PMID:26676567 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
Chloroquine results in increased phosphorylation of MAPK1 protein [Chloroquine co-treated with Cannabidiol] affects the phosphorylation of MAPK1 protein; Chloroquine affects the reaction [Cannabidiol affects the phosphorylation of MAPK1 protein] Chloroquine results in decreased phosphorylation of MAPK1 protein Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK1 protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]] |
CTD |
PMID:18055026 PMID:22341560 PMID:28134560 PMID:31310755 PMID:32060308 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK3 protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]] [Chloroquine co-treated with Cannabidiol] affects the phosphorylation of MAPK3 protein; Chloroquine affects the reaction [Cannabidiol affects the phosphorylation of MAPK3 protein] Chloroquine results in decreased phosphorylation of MAPK3 protein Chloroquine results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:18055026 PMID:22341560 PMID:28134560 PMID:31310755 PMID:32060308 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Chloroquine promotes the reaction [Rotenone results in increased phosphorylation of MAPK8 protein] Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK8 protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased phosphorylation of MAPK8 protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK8 protein]] |
CTD |
PMID:22341560 PMID:28134560 PMID:31648047 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
affects expression multiple interactions |
EXP |
Chloroquine affects the expression of MAPT mRNA; Chloroquine affects the expression of MAPT protein Chloroquine affects the localization of and affects the degradation of MAPT protein |
CTD |
PMID:9690670 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
multiple interactions |
ISO |
Chloroquine promotes the reaction [usnic acid results in decreased expression of MCL1 protein] |
CTD |
PMID:25078063 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mir155 |
microRNA 155 |
multiple interactions |
ISO |
[Carboplatin co-treated with Chloroquine] results in increased expression of MIR155 mRNA |
CTD |
PMID:27692344 |
|
NCBI chr11:23,774,654...23,774,718
Ensembl chr11:23,774,654...23,774,718
|
|
G |
Mir224 |
microRNA 224 |
|
ISO |
inhibits the reaction [Amiodarone decreased expression of miR224 in a human hepatoma cell line] |
RGD |
PMID:23913306 |
RGD:18182923 |
NCBI chr X:150,065,088...150,065,169
Ensembl chr X:150,065,088...150,065,169
|
|
G |
Mki67 |
marker of proliferation Ki-67 |
multiple interactions |
ISO |
[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein; CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]; Doxorubicin promotes the reaction [CEBPB protein alternative form promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of MKI67 protein]] [Chloroquine co-treated with flavokawain B] results in decreased expression of MKI67 protein |
CTD |
PMID:30025493 PMID:30482226 |
|
NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of MMP13 mRNA; Chloroquine results in increased expression of MMP13 protein Oxygen deficiency promotes the reaction [Chloroquine results in increased expression of MMP13 mRNA]; TLR9 protein promotes the reaction [Oxygen deficiency promotes the reaction [Chloroquine results in increased expression of MMP13 mRNA]] Chloroquine inhibits the reaction [CPG-oligonucleotide results in increased expression of MMP13 mRNA]; Chloroquine inhibits the reaction [CPG-oligonucleotide results in increased secretion of MMP13 protein] |
CTD |
PMID:23331101 PMID:24273604 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of MMP2 mRNA; Chloroquine results in decreased expression of MMP2 protein Sirolimus inhibits the reaction [Chloroquine results in decreased expression of MMP2 protein] |
CTD |
PMID:24273604 PMID:34278709 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression decreases expression |
ISO |
Chloroquine inhibits the reaction [Artesunate results in decreased expression of MMP9 mRNA]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Oxygen deficiency inhibits the reaction [Chloroquine results in decreased expression of MMP9 mRNA] Chloroquine results in increased expression of MMP9 mRNA Chloroquine results in decreased expression of MMP9 mRNA; Chloroquine results in decreased expression of MMP9 protein |
CTD |
PMID:24145604 PMID:24273604 PMID:30551460 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
decreases phosphorylation increases expression multiple interactions |
ISO |
Chloroquine results in decreased phosphorylation of MTOR protein Chloroquine results in increased expression of MTOR protein Chloroquine inhibits the reaction [formosanin C results in decreased phosphorylation of MTOR protein] |
CTD |
PMID:25884947 PMID:27180204 PMID:31310755 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of MTTP protein [benzyloxycarbonylleucyl-leucyl-leucine aldehyde co-treated with Chloroquine] results in increased expression of MTTP protein |
CTD |
PMID:34516972 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Muc1 |
mucin 1, cell surface associated |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [MUC1 affects the expression of EGFR protein] |
CTD |
PMID:22457794 |
|
NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Myd88 |
MYD88, innate immune signal transduction adaptor |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of MYD88 mRNA] |
CTD |
PMID:22341560 |
|
NCBI chr 8:119,074,439...119,078,508
Ensembl chr 8:119,074,437...119,079,415
|
|
G |
Myom2 |
myomesin 2 |
increases expression |
EXP |
Chloroquine results in increased expression of MYOM2 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr16:74,520,148...74,592,658
Ensembl chr16:74,520,157...74,592,772
|
|
G |
Nacc1 |
nucleus accumbens associated 1 |
multiple interactions |
ISO |
Chloroquine affects the reaction [NACC1 affects the susceptibility to Cisplatin] |
CTD |
PMID:21743489 |
|
NCBI chr19:23,468,688...23,486,528
Ensembl chr19:23,468,419...23,486,528
|
|
G |
Ncoa4 |
nuclear receptor coactivator 4 |
increases expression multiple interactions |
ISO EXP |
Chloroquine results in increased expression of NCOA4 mRNA Chloroquine inhibits the reaction [erastin results in decreased expression of NCOA4 protein] Chloroquine inhibits the reaction [Artesunate results in decreased expression of NCOA4 mRNA] |
CTD |
PMID:30551460 PMID:32937103 |
|
NCBI chr16:7,389,222...7,409,564
Ensembl chr16:7,366,542...7,409,641 Ensembl chr16:7,366,542...7,409,641
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
multiple interactions |
ISO |
Chloroquine affects the reaction [NDRG1 protein affects the lipidation of MAP1LC3B protein]; Chloroquine inhibits the reaction [Cycloheximide results in decreased expression of NDRG1 protein]; Chloroquine promotes the reaction [fosbretabulin results in increased expression of NDRG1 protein]; NDRG1 protein affects the reaction [Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of CASP3 protein]]; NDRG1 protein affects the reaction [Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]]; NDRG1 protein affects the reaction [Chloroquine results in increased cleavage of CASP3 protein]; NDRG1 protein affects the reaction [Chloroquine results in increased cleavage of PARP1 protein]; NDRG1 protein affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein]; NDRG1 protein affects the susceptibility to [fosbretabulin co-treated with Chloroquine] |
CTD |
PMID:28906492 |
|
NCBI chr 7:98,684,487...98,725,869
Ensembl chr 7:98,684,487...98,725,880
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of NFKB1 protein Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased activity of NFKB1 protein] |
CTD |
PMID:22341560 PMID:26116531 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein; Chloroquine inhibits the reaction [Bortezomib results in increased degradation of NFKBIA protein]; LAMP2 protein alternative form affects the reaction [[quizartinib co-treated with spautin-1 co-treated with Chloroquine] results in increased transport of and affects the localization of NFKBIA protein] Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]] |
CTD |
PMID:24085292 PMID:28134560 PMID:30821613 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nod2 |
nucleotide-binding oligomerization domain containing 2 |
multiple interactions |
ISO |
NOD2 protein affects the reaction [Chloroquine results in increased lipidation of MAP1LC3B protein] |
CTD |
PMID:23880069 |
|
NCBI chr19:18,379,720...18,422,817
Ensembl chr19:18,382,439...18,417,177
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [sunitinib results in increased expression of NOS2 protein] |
CTD |
PMID:24751611 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Notch1 |
notch receptor 1 |
multiple interactions |
ISO |
[Fluorouracil co-treated with Chloroquine] results in increased expression of NOTCH1 protein |
CTD |
PMID:29917191 |
|
NCBI chr 3:9,277,955...9,323,531
Ensembl chr 3:9,278,086...9,323,531
|
|
G |
Nppc |
natriuretic peptide C |
decreases expression |
EXP |
Chloroquine results in decreased expression of NPPC mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 9:87,320,051...87,324,251
Ensembl chr 9:87,320,051...87,324,251
|
|
G |
Nqo2 |
N-ribosyldihydronicotinamide:quinone reductase 2 |
multiple interactions |
ISO |
Chloroquine binds to and results in decreased activity of NQO2 protein |
CTD |
PMID:15078100 |
|
NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320
|
|
G |
Nr0b2 |
nuclear receptor subfamily 0, group B, member 2 |
decreases expression |
ISO |
Chloroquine results in decreased expression of NR0B2 mRNA |
CTD |
PMID:24189133 |
|
NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions |
ISO |
Chloroquine binds to and results in increased activity of NR4A2 protein |
CTD |
PMID:31175960 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Ocln |
occludin |
increases expression |
ISO |
Chloroquine results in increased expression of OCLN mRNA |
CTD |
PMID:25752684 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Optn |
optineurin |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] |
CTD |
PMID:25884947 |
|
NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251
|
|
G |
Osgin1 |
oxidative stress induced growth inhibitor 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of OSGIN1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr19:47,471,750...47,500,517
Ensembl chr19:47,492,171...47,500,516
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO EXP |
Chloroquine inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein] Chloroquine results in increased cleavage of PARP1 protein [Chloroquine co-treated with 3-methyladenine] results in increased cleavage of PARP1 protein; [Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [Chloroquine results in increased cleavage of PARP1 protein]; Arsenic Trioxide promotes the reaction [Chloroquine results in increased cleavage of PARP1 protein]; Chloroquine inhibits the reaction [betulin results in increased cleavage of PARP1 protein]; Chloroquine inhibits the reaction [Cadmium results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]; NDRG1 protein affects the reaction [Chloroquine promotes the reaction [fosbretabulin results in increased cleavage of PARP1 protein]]; NDRG1 protein affects the reaction [Chloroquine results in increased cleavage of PARP1 protein]; PARP1 protein affects the reaction [Chloroquine promotes the reaction [[ferric ammonium citrate results in increased abundance of Iron] which results in increased lipidation of MAP1LC3B protein]] Chloroquine promotes the reaction [Cadmium results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [Methamphetamine results in increased cleavage of PARP1 protein] |
CTD |
PMID:27658547 PMID:28906492 PMID:29111403 PMID:30025493 PMID:30338810 PMID:30985881 PMID:31310755 PMID:32190974 PMID:34374793 PMID:34826546 PMID:35022897 More...
|
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Acetaminophen results in increased expression of PINK1 protein]; Chloroquine inhibits the reaction [coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of PINK1 protein]] |
CTD |
PMID:33271250 |
|
NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635
|
|
G |
Plin3 |
perilipin 3 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [CpG ODN 1826 results in increased expression of PLIN3 mRNA]; Chloroquine inhibits the reaction [CpG ODN 1826 results in increased expression of PLIN3 protein] |
CTD |
PMID:20628022 |
|
NCBI chr 9:1,111,178...1,123,117
Ensembl chr 9:1,102,366...1,123,147
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of PMAIP1 protein] |
CTD |
PMID:35561756 |
|
NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [POMC protein modified form results in increased chemical synthesis of Adrenal Cortex Hormones] |
CTD |
PMID:2993719 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
multiple interactions |
ISO |
Chloroquine analog binds to and results in decreased activity of PPT1 protein; Chloroquine binds to and results in decreased activity of PPT1 protein |
CTD |
PMID:30442709 |
|
NCBI chr 5:135,121,176...135,141,076
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO EXP |
Chloroquine inhibits the reaction [Acetaminophen results in increased expression of PRKN protein]; Chloroquine inhibits the reaction [coenzyme Q10 promotes the reaction [Acetaminophen results in increased expression of PRKN protein]] Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of PRKN protein]] |
CTD |
PMID:33271250 PMID:35104487 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Prlr |
prolactin receptor |
decreases expression |
EXP |
Chloroquine results in decreased expression of PRLR mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 2:59,134,147...59,324,719
Ensembl chr 2:59,134,588...59,324,718
|
|
G |
Pten |
phosphatase and tensin homolog |
increases expression |
ISO |
Chloroquine results in increased expression of PTEN mRNA |
CTD |
PMID:31310755 |
|
NCBI chr 1:230,631,303...230,696,754
Ensembl chr 1:230,630,338...230,696,838
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]] |
CTD |
PMID:24145604 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rbpj |
recombination signal binding protein for immunoglobulin kappa J region |
increases expression |
ISO |
Chloroquine results in increased expression of RBPJ protein |
CTD |
PMID:22302987 |
|
NCBI chr14:57,338,493...57,523,330
Ensembl chr14:57,338,507...57,523,353
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity multiple interactions decreases expression |
ISO EXP |
Chloroquine results in increased activity of RELA protein Chloroquine inhibits the reaction [[Diethylnitrosamine co-treated with N-nitrosomorpholine] results in increased expression of RELA protein] Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of and affects the localization of RELA protein]; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of RELA protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of and affects the localization of RELA protein]] Chloroquine results in decreased expression of RELA protein [Chloroquine co-treated with Cannabidiol] results in decreased phosphorylation of RELA protein; Acetylcysteine inhibits the reaction [Chloroquine results in increased activity of RELA protein]; diphenyliodonium inhibits the reaction [Chloroquine results in increased activity of RELA protein] |
CTD |
PMID:15139008 PMID:24990399 PMID:26116531 PMID:28134560 PMID:32060308 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rheb |
Ras homolog, mTORC1 binding |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [EGF protein results in increased expression of RHEB protein] |
CTD |
PMID:22689575 |
|
NCBI chr 4:10,278,970...10,320,160
Ensembl chr 4:10,279,370...10,320,160
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
decreases phosphorylation multiple interactions increases expression |
ISO EXP |
Chloroquine results in decreased phosphorylation of RPS6KB1 protein Chloroquine inhibits the reaction [EGF protein results in increased phosphorylation of RPS6KB1 protein] Chloroquine results in increased expression of RPS6KB1 protein modified form |
CTD |
PMID:22689575 PMID:25884947 PMID:31310755 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [[Dexamethasone co-treated with ascorbate-2-phosphate co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 mRNA] |
CTD |
PMID:23111315 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
decreases expression multiple interactions |
EXP ISO |
Chloroquine results in decreased expression of SCARB1 mRNA [Chloroquine co-treated with Lovastatin] inhibits the reaction [SCARB1 protein results in increased abundance of Progesterone] |
CTD |
PMID:19393257 PMID:20404351 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sccpdh |
saccharopine dehydrogenase (putative) |
decreases expression |
EXP |
Chloroquine results in decreased expression of SCCPDH mRNA |
CTD |
PMID:19393257 |
|
NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222
|
|
G |
Scd |
stearoyl-CoA desaturase |
decreases expression |
EXP |
Chloroquine results in decreased expression of SCD1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Senp6 |
SUMO specific peptidase 6 |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with Chloroquine] results in increased expression of SENP6 protein |
CTD |
PMID:26807181 |
|
NCBI chr 8:80,988,675...81,071,606
Ensembl chr 8:80,989,052...81,067,170
|
|
G |
Serpina3n |
serine (or cysteine) peptidase inhibitor, clade A, member 3N |
affects localization |
EXP |
Chloroquine affects the localization of SERPINA3 protein |
CTD |
PMID:8616629 |
|
NCBI chr 6:123,323,632...123,331,166
Ensembl chr 6:123,323,629...123,332,433
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Chloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein] |
CTD |
PMID:30341573 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slc12a1 |
solute carrier family 12 member 1 |
decreases expression |
ISO |
Chloroquine results in decreased expression of SLC12A1 protein |
CTD |
PMID:22791344 |
|
NCBI chr 3:112,406,140...112,482,913
Ensembl chr 3:112,406,140...112,482,899
|
|
G |
Slc14a2 |
solute carrier family 14 member 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [AVP protein affects the localization of SLC14A2 protein] |
CTD |
PMID:22791344 |
|
NCBI chr18:71,612,460...72,039,462
Ensembl chr18:71,612,460...71,792,968
|
|
G |
Slc19a3 |
solute carrier family 19 member 3 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [SLC19A3 protein results in increased uptake of Metformin]; Chloroquine inhibits the reaction [SLC19A3 protein results in increased uptake of Thiamine] |
CTD |
PMID:26528626 |
|
NCBI chr 9:84,275,722...84,299,368
Ensembl chr 9:84,277,024...84,299,337
|
|
G |
Slc22a1 |
solute carrier family 22 member 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:27504015 |
|
NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium] |
CTD |
PMID:27504015 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions affects localization |
EXP |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Chloroquine affects the localization of SLC2A4 protein] which results in increased uptake of Glucose]; 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Chloroquine affects the localization of SLC2A4 protein]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Chloroquine affects the localization of SLC2A4 protein]; [[Chloroquine results in increased abundance of Calcium] which affects the localization of SLC2A4 protein] which results in increased uptake of Glucose; [Chloroquine affects the localization of SLC2A4 protein] which results in increased uptake of Glucose; [Chloroquine results in increased abundance of Calcium] which affects the localization of SLC2A4 protein; gallein inhibits the reaction [Chloroquine affects the localization of SLC2A4 protein] |
CTD |
PMID:27160165 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Cisplatin results in decreased expression of SLC7A11 protein] |
CTD |
PMID:34302894 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Slco1a4 |
solute carrier organic anion transporter family, member 1a4 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [SLCO1A2 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:27504015 |
|
NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Dibutyl Phthalate results in increased expression of SNAI1 mRNA] |
CTD |
PMID:30053495 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions decreases expression |
ISO |
Quercetin inhibits the reaction [Chloroquine results in decreased expression of SOD1 mRNA] |
CTD |
PMID:23607047 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sort1 |
sortilin 1 |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of SORT1 protein Chloroquine affects the reaction [SORT1 protein affects the reaction [LDLR protein affects the abundance of Cholesterol]] |
CTD |
PMID:25805502 PMID:30950489 |
|
NCBI chr 2:195,924,033...196,002,354
Ensembl chr 2:195,924,099...196,002,354
|
|
G |
Sp1 |
Sp1 transcription factor |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [[WEHI-539 co-treated with venetoclax] results in increased expression of SP1 protein] |
CTD |
PMID:35561756 |
|
NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO EXP |
Chloroquine inhibits the reaction [[Simvastatin co-treated with Metformin] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [[venetoclax co-treated with WEHI-539] results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [ANGPTL8 protein results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Artesunate results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Cisplatin results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [cryptotanshinone results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [dactolisib results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [dorsomorphin results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Doxorubicin results in increased degradation of SQSTM1 protein]; Chloroquine inhibits the reaction [formosanin C results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [fosbretabulin results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Resveratrol results in increased degradation of SQSTM1 protein]; Chloroquine inhibits the reaction [sepantronium results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Sorafenib results in decreased expression of SQSTM1 protein]; Chloroquine promotes the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; Chloroquine promotes the reaction [Arsenic Trioxide results in increased expression of SQSTM1 protein]; Chloroquine promotes the reaction [lead acetate results in increased expression of SQSTM1 protein]; Chloroquine promotes the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in increased expression of SQSTM1 protein]; ERGIC3 protein promotes the reaction [Chloroquine results in increased expression of SQSTM1 protein] [bisphenol A co-treated with Chloroquine] results in increased expression of SQSTM1 protein; Chloroquine inhibits the reaction [Acetaminophen results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Arsenic Trioxide results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [coenzyme Q10 promotes the reaction [Acetaminophen results in decreased expression of SQSTM1 protein]]; Chloroquine inhibits the reaction [Sunitinib results in decreased expression of SQSTM1 protein]; Chloroquine promotes the reaction [triethylene glycol dimethacrylate results in increased expression of SQSTM1 protein] Chloroquine inhibits the reaction [cadmium acetate results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Cadmium results in decreased expression of SQSTM1 protein]; Chloroquine inhibits the reaction [Venlafaxine Hydrochloride inhibits the reaction [Rotenone results in decreased expression of SQSTM1 protein]]; Chloroquine promotes the reaction [Glucose results in increased expression of SQSTM1 protein]; Chloroquine promotes the reaction [manganese chloride results in increased expression of SQSTM1 protein]; Chloroquine promotes the reaction [Resveratrol promotes the reaction [Glucose results in increased expression of SQSTM1 protein]] |
CTD |
PMID:21858812 PMID:22927544 PMID:23651616 PMID:24262987 PMID:24751611 PMID:25412314 PMID:25884947 PMID:25943029 PMID:27180204 PMID:27588471 PMID:27658547 PMID:28275691 PMID:28600121 PMID:28713934 PMID:28906492 PMID:29222055 PMID:29248574 PMID:29870746 PMID:30208301 PMID:30237538 PMID:30280407 PMID:30338810 PMID:30550853 PMID:30551460 PMID:31586597 PMID:31837377 PMID:31900833 PMID:32186374 PMID:32693121 PMID:32702505 PMID:33070465 PMID:33271250 PMID:33462182 PMID:33684387 PMID:34186417 PMID:34405320 PMID:34520793 PMID:34842334 PMID:35104487 PMID:35561756 More...
|
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Ssb |
small RNA binding exonuclease protection factor La |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [SSB protein results in increased expression of CXCL8 mRNA]; Chloroquine inhibits the reaction [SSB protein results in increased secretion of CXCL8 protein] |
CTD |
PMID:25915936 |
|
NCBI chr 3:54,616,616...54,626,203
Ensembl chr 3:54,616,619...54,626,203
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
EXP |
Chloroquine results in decreased expression of STAR mRNA |
CTD |
PMID:19393257 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stc2 |
stanniocalcin 2 |
decreases expression |
EXP |
Chloroquine results in decreased expression of STC2 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Strap |
serine/threonine kinase receptor associated protein |
decreases expression |
EXP |
Chloroquine results in decreased expression of STRAP mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 4:170,646,042...170,660,291
Ensembl chr 4:170,646,001...170,660,828
|
|
G |
Syp |
synaptophysin |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Nanotubes, Carbon results in decreased expression of SYP] |
CTD |
PMID:26327526 |
|
NCBI chr X:14,849,444...14,864,553
Ensembl chr X:14,849,444...14,864,745
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions increases expression |
ISO |
Chloroquine promotes the reaction [VCP protein mutant form results in increased expression of TARDBP protein] Chloroquine results in increased expression of TARDBP protein |
CTD |
PMID:25884947 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tet2 |
tet methylcytosine dioxygenase 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [dorsomorphin results in decreased expression of TET2 mRNA]; Chloroquine inhibits the reaction [dorsomorphin results in decreased expression of TET2 protein] |
CTD |
PMID:31900833 |
|
NCBI chr 2:221,988,645...222,072,813
Ensembl chr 2:221,988,645...222,072,534
|
|
G |
Tgoln2 |
trans-golgi network protein 2 |
affects localization |
ISO |
Chloroquine affects the localization of TGOLN2 protein |
CTD |
PMID:29940786 |
|
NCBI chr 4:104,663,356...104,671,208
Ensembl chr 4:104,663,353...104,671,164
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [[THRA protein co-treated with Triiodothyronine] results in decreased expression of SQSTM1 protein] |
CTD |
PMID:24262987 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Ticam2 |
TIR domain containing adaptor molecule 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of TICAM2 mRNA] |
CTD |
PMID:22341560 |
|
NCBI chr18:39,289,902...39,311,462
Ensembl chr18:39,294,453...39,311,462
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
decreases expression multiple interactions |
ISO |
Chloroquine results in decreased expression of TIMP1 mRNA Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TIMP1 protein] Chloroquine inhibits the reaction [Artesunate results in increased expression of TIMP1 mRNA] |
CTD |
PMID:22341560 PMID:30551460 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TIMP2 protein] |
CTD |
PMID:22341560 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tlr3 |
toll-like receptor 3 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [Poly I-C results in increased activity of TLR3 protein] |
CTD |
PMID:21398612 |
|
NCBI chr16:46,821,980...46,837,900
Ensembl chr16:46,822,039...46,836,545
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [lipopolysaccharide, Escherichia coli O111 B4 affects the localization of TLR4 protein] |
CTD |
PMID:22341560 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tlr7 |
toll-like receptor 7 |
decreases activity |
ISO |
Chloroquine results in decreased activity of TLR7 protein |
CTD |
PMID:27385120 |
|
NCBI chr X:27,027,380...27,054,309
Ensembl chr X:27,027,425...27,054,754
|
|
G |
Tlr8 |
toll-like receptor 8 |
decreases activity |
ISO |
Chloroquine results in decreased activity of TLR8 protein |
CTD |
PMID:27385120 |
|
NCBI chr X:27,091,780...27,116,092
Ensembl chr X:27,091,778...27,116,549
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions decreases expression decreases activity increases expression |
ISO EXP |
Chloroquine inhibits the reaction [CpG ODN 2006 results in increased activity of TLR9 protein]; Chloroquine inhibits the reaction [CpG ODN 2395 results in increased activity of TLR9 protein]; Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of TLR9 mRNA]; Oxygen deficiency inhibits the reaction [Chloroquine results in increased expression of TLR9 mRNA]; TLR9 protein promotes the reaction [Oxygen deficiency promotes the reaction [Chloroquine results in increased expression of MMP13 mRNA]] Chloroquine results in decreased expression of TLR9 protein Chloroquine inhibits the reaction [[Diethylnitrosamine co-treated with N-nitrosomorpholine] results in increased expression of TLR9 protein] Chloroquine results in decreased activity of TLR9 protein |
CTD |
PMID:21398612 PMID:22595112 PMID:24273604 PMID:24990399 |
|
NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796
|
|
G |
Tm7sf2 |
transmembrane 7 superfamily member 2 |
decreases expression |
EXP |
Chloroquine results in decreased expression of TM7SF2 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 1:203,355,930...203,360,287
Ensembl chr 1:203,355,931...203,360,270
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions decreases secretion increases expression |
ISO EXP |
Chloroquine results in decreased expression of TNF protein Chloroquine inhibits the reaction [3,4-dihydroxyphenylethanol inhibits the reaction [Hydrogen Peroxide results in increased secretion of TNF protein]] [Chloroquine co-treated with TNF protein] results in increased expression of MAP1LC3B protein alternative form; Chloroquine inhibits the reaction [alpinetin inhibits the reaction [TNF protein results in increased cleavage of CASP3 protein]]; Chloroquine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [TNF protein results in increased expression of PTGS2 protein]]; Chloroquine promotes the reaction [[TNF protein co-treated with Resveratrol] results in increased expression of MAP1LC3B protein alternative form]; Chloroquine promotes the reaction [TNF protein results in increased expression of and results in increased lipidation of MAP1LC3B protein]; TNF protein promotes the reaction [Chloroquine results in increased expression of and results in increased lipidation of MAP1LC3B protein] Chloroquine results in decreased secretion of TNF protein Chloroquine results in increased expression of TNF Chloroquine inhibits the reaction [CPG-oligonucleotide results in increased secretion of TNF protein]; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]; Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNF protein]; Chloroquine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Chloroquine inhibits the reaction [Resveratrol inhibits the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TNF protein]]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TNF mRNA]; Chloroquine promotes the reaction [[Choline deficiency co-treated with Methionine deficiency] results in increased expression of TNF protein]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]] |
CTD |
PMID:8244452 PMID:9002011 PMID:9799232 PMID:10638776 PMID:15139008 PMID:22341560 PMID:24145604 PMID:26498332 PMID:28134560 PMID:31332898 PMID:31676321 PMID:33609687 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf10b |
TNF receptor superfamily member 10b |
increases expression |
ISO |
Chloroquine results in increased expression of TNFRSF10A protein |
CTD |
PMID:27692344 |
|
NCBI chr15:44,839,818...44,867,582
Ensembl chr15:44,840,386...44,867,467
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNFRSF1A protein] |
CTD |
PMID:22341560 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tnfrsf1b |
TNF receptor superfamily member 1B |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of TNFRSF1B protein] |
CTD |
PMID:22341560 |
|
NCBI chr 5:157,070,642...157,104,216
Ensembl chr 5:157,070,642...157,104,206
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [Triiodothyronine results in increased expression of TOMM20 protein] |
CTD |
PMID:30209975 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
increases activity multiple interactions |
ISO |
Chloroquine results in increased activity of TP53; Chloroquine results in increased activity of TP53 protein Chloroquine inhibits the reaction [Doxorubicin results in increased expression of TP53 protein] TRP53 mutant form inhibits the reaction [Chloroquine results in increased activity of CASP3 protein] |
CTD |
PMID:11589424 PMID:12082016 PMID:18089834 PMID:22927544 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of TRIB3 protein 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Chloroquine results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased expression of TRIB3 protein] 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo(h)(1,6)naphthyridin-2(1H)-one inhibits the reaction [Chloroquine results in increased expression of TRIB3 protein]; [Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein; Betulinic Acid inhibits the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [[Bortezomib co-treated with Chloroquine] results in increased expression of TRIB3 protein]; Doxorubicin promotes the reaction [Chloroquine results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [[Chloroquine co-treated with Bortezomib] results in increased expression of TRIB3 protein]; Nitroprusside promotes the reaction [Chloroquine results in increased expression of TRIB3 protein] |
CTD |
PMID:30482226 |
|
NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497
|
|
G |
Trim63 |
tripartite motif containing 63 |
affects expression |
EXP |
Chloroquine affects the expression of TRIM63 mRNA |
CTD |
PMID:19296457 |
|
NCBI chr 5:146,533,492...146,547,332
Ensembl chr 5:146,533,507...146,547,322
|
|
G |
Trpc1 |
transient receptor potential cation channel, subfamily C, member 1 |
multiple interactions |
EXP |
Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of TRPC1 mRNA]; Chloroquine inhibits the reaction [Oxygen deficiency results in increased expression of TRPC1 protein] |
CTD |
PMID:32956540 |
|
NCBI chr 8:96,263,322...96,314,197
Ensembl chr 8:96,263,329...96,314,276
|
|
G |
Ubc |
ubiquitin C |
increases expression |
EXP |
Chloroquine results in increased expression of UBC mRNA |
CTD |
PMID:19296457 |
|
NCBI chr12:31,238,889...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Usp2 |
ubiquitin specific peptidase 2 |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of USP2 mRNA Chloroquine promotes the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of USP2 mRNA]; lipopolysaccharide, E coli O55-B5 promotes the reaction [Chloroquine results in increased expression of USP2 mRNA] |
CTD |
PMID:28134560 |
|
NCBI chr 8:44,411,457...44,439,668
Ensembl chr 8:44,411,607...44,438,331
|
|
G |
Usp25 |
ubiquitin specific peptidase 25 |
multiple interactions increases expression |
ISO |
[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of USP25 mRNA; [lipopolysaccharide, E coli O55-B5 co-treated with Chloroquine] results in increased expression of USP25 protein; Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of USP25 mRNA]; lipopolysaccharide, E coli O55-B5 inhibits the reaction [Chloroquine results in increased expression of USP25 mRNA]; USP25 protein affects the reaction [[Chloroquine co-treated with lipopolysaccharide, E coli O55-B5] results in increased expression of USP25 mRNA]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 affects the localization of IRF3 protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased activity of and affects the localization of RELA protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 mRNA]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IFNB1 protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of IL6 mRNA]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased expression of TNF mRNA]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK1 protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK3 protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of MAPK8 protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased phosphorylation of NFKBIA protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of IL6 protein]]; USP25 protein affects the reaction [Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in increased secretion of TNF protein]] Chloroquine results in increased expression of USP25 mRNA; Chloroquine results in increased expression of USP25 protein |
CTD |
PMID:28134560 |
|
NCBI chr11:15,603,654...15,711,356
Ensembl chr11:15,603,881...15,711,348
|
|
G |
Usp28 |
ubiquitin specific peptidase 28 |
increases expression multiple interactions |
ISO |
Chloroquine results in increased expression of USP28 mRNA Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of USP28 mRNA]; lipopolysaccharide, E coli O55-B5 inhibits the reaction [Chloroquine results in increased expression of USP28 mRNA] |
CTD |
PMID:28134560 |
|
NCBI chr 8:49,325,766...49,386,229
Ensembl chr 8:49,325,867...49,386,229
|
|
G |
Usp7 |
ubiquitin specific peptidase 7 |
multiple interactions increases expression |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of USP7 mRNA]; lipopolysaccharide, E coli O55-B5 inhibits the reaction [Chloroquine results in increased expression of USP7 mRNA] |
CTD |
PMID:28134560 |
|
NCBI chr10:6,880,684...6,925,033
Ensembl chr10:6,828,795...6,925,355
|
|
G |
Usp8 |
ubiquitin specific peptidase 8 |
multiple interactions |
ISO |
[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] promotes the reaction [Chloroquine results in increased cleavage of PARP1 protein]; Chloroquine promotes the reaction [[Cysteine Proteinase Inhibitors results in decreased activity of USP8 protein] which results in increased cleavage of PARP1 protein] |
CTD |
PMID:35022897 |
|
NCBI chr 3:113,962,136...114,009,683
Ensembl chr 3:113,962,164...114,009,666
|
|
G |
Vcp |
valosin-containing protein |
multiple interactions |
ISO |
Chloroquine promotes the reaction [VCP protein mutant form results in increased expression of TARDBP protein] Chloroquine inhibits the reaction [VCP protein mutant form results in decreased expression of MAP1LC3B protein]; Chloroquine inhibits the reaction [VCP protein mutant form results in increased expression of OPTN protein] |
CTD |
PMID:25884947 |
|
NCBI chr 5:57,210,167...57,229,571
Ensembl chr 5:57,210,168...57,229,571
|
|
G |
Vsnl1 |
visinin-like 1 |
decreases expression |
EXP |
Chloroquine results in decreased expression of VSNL1 mRNA |
CTD |
PMID:19393257 |
|
NCBI chr 6:34,038,641...34,159,479
Ensembl chr 6:34,038,642...34,159,479
|
|
G |
Xcl1 |
X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
Chloroquine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of XCL1 protein] |
CTD |
PMID:22341560 |
|
NCBI chr13:77,248,865...77,252,308
Ensembl chr13:77,248,717...77,252,329
|
|
G |
Xpo1 |
exportin 1 |
multiple interactions |
ISO |
Chloroquine promotes the reaction [XPO1 protein binds to BECN1 protein]; Chloroquine promotes the reaction [XPO1 protein binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr14:97,233,263...97,275,536
Ensembl chr14:97,233,270...97,275,498
|
|
G |
Ywhaq |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, theta |
multiple interactions |
ISO |
Chloroquine promotes the reaction [ABL1 protein mutant form binds to YWHAQ protein]; Chloroquine promotes the reaction [XPO1 protein binds to YWHAQ protein] |
CTD |
PMID:33070465 |
|
NCBI chr 6:40,935,714...40,966,240
Ensembl chr 6:40,935,949...40,966,273
|
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of AGO3 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230
|
|
G |
Akap9 |
A-kinase anchoring protein 9 |
multiple interactions |
ISO |
Emetine inhibits the reaction [sodium arsenite affects the localization of AKAP9 protein] |
CTD |
PMID:19073175 |
|
NCBI chr 4:30,056,738...30,192,716
Ensembl chr 4:30,056,738...30,192,606
|
|
G |
Ar |
androgen receptor |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of AR protein |
CTD |
PMID:25752796 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Brca1 |
BRCA1, DNA repair associated |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of BRCA1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304
|
|
G |
Caprin1 |
cell cycle associated protein 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [sodium arsenite affects the localization of CAPRIN1 protein] |
CTD |
PMID:19073175 |
|
NCBI chr 3:90,152,305...90,230,447
Ensembl chr 3:90,153,620...90,230,502
|
|
G |
Casp3 |
caspase 3 |
increases activity |
ISO |
Emetine results in increased activity of CASP3 protein |
CTD |
PMID:14502240 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Emetine results in increased activity of CASP9 protein |
CTD |
PMID:14502240 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [sodium arsenite affects the localization of CCAR1 protein] |
CTD |
PMID:19073175 |
|
NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,466,469...68,467,941
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Emetine results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of CREB1 mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of ESR2 protein |
CTD |
PMID:25752796 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Emetine results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK1 protein] Emetine results in decreased phosphorylation of MAPK1 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein] |
CTD |
PMID:15772366 PMID:26332055 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Emetine results in increased phosphorylation of and results in increased activity of MAPK14 protein; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK1 protein]; MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] |
CTD |
PMID:16364386 PMID:26332055 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation multiple interactions decreases phosphorylation |
ISO |
Emetine results in increased phosphorylation of MAPK3 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased phosphorylation of MAPK3 protein] 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15772366 PMID:26332055 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK8 protein] |
CTD |
PMID:15772366 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapk9 |
mitogen-activated protein kinase 9 |
multiple interactions increases phosphorylation |
ISO |
4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [Emetine results in increased phosphorylation of MAPK9 protein] |
CTD |
PMID:15772366 |
|
NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases expression |
ISO |
Emetine results in decreased expression of MAPT protein |
CTD |
PMID:16930453 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
decreases activity multiple interactions decreases expression |
ISO |
Emetine results in decreased activity of MMP2 protein MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP2 protein] Emetine results in decreased expression of MMP2 mRNA |
CTD |
PMID:26332055 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions decreases expression decreases activity |
ISO |
MAPK14 mutant form inhibits the reaction [Emetine results in decreased activity of MMP9 protein] Emetine results in decreased expression of MMP9 mRNA |
CTD |
PMID:26332055 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
multiple interactions |
ISO |
Emetine inhibits the reaction [pregna-4,17-diene-3,16-dione results in decreased activity of NR1H4 protein] |
CTD |
PMID:25257666 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
Emetine results in increased cleavage of PARP1 protein |
CTD |
PMID:21256112 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pgr |
progesterone receptor |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of PGR protein |
CTD |
PMID:25752796 |
|
NCBI chr 8:6,073,216...6,131,552
Ensembl chr 8:6,072,673...6,131,344
|
|
G |
Reck |
reversion-inducing-cysteine-rich protein with kazal motifs |
decreases expression |
ISO |
Emetine results in decreased expression of RECK mRNA |
CTD |
PMID:26332055 |
|
NCBI chr 5:58,102,915...58,169,513
Ensembl chr 5:58,102,981...58,169,502
|
|
G |
Rictor |
RPTOR independent companion of MTOR, complex 2 |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of RICTOR mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr 2:55,811,877...55,903,893
Ensembl chr 2:55,811,322...55,901,426
|
|
G |
Tardbp |
TAR DNA binding protein |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIA1 protein]; Emetine affects the reaction [TARDBP protein binds to TIAL1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 5:159,050,518...159,062,218
Ensembl chr 5:159,051,799...159,062,055
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases activity |
ISO |
Emetine results in decreased activity of TGFB1 protein |
CTD |
PMID:31652400 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of THRA protein |
CTD |
PMID:25752796 |
|
NCBI chr10:83,701,885...83,729,408
Ensembl chr10:83,700,755...83,729,936
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions |
ISO |
Emetine binds to and results in decreased activity of THRB protein |
CTD |
PMID:25752796 |
|
NCBI chr15:7,685,180...8,031,920
Ensembl chr15:7,685,180...7,882,916
|
|
G |
Tia1 |
TIA1 cytotoxic granule-associated RNA binding protein |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIA1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 4:118,852,765...118,883,252
Ensembl chr 4:118,852,837...118,880,586
|
|
G |
Tial1 |
Tia1 cytotoxic granule-associated RNA binding protein-like 1 |
multiple interactions |
ISO |
Emetine affects the reaction [TARDBP protein binds to TIAL1 protein] |
CTD |
PMID:19765185 |
|
NCBI chr 1:183,008,358...183,045,092
Ensembl chr 1:183,009,253...183,031,637
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Emetine results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Xiap |
X-linked inhibitor of apoptosis |
multiple interactions |
ISO |
Emetine inhibits the reaction [Thapsigargin affects the localization of XIAP mRNA] |
CTD |
PMID:29576526 |
|
NCBI chr X:120,890,537...120,938,413
Ensembl chr X:120,897,907...120,934,700
|
|
|
G |
Alpl |
alkaline phosphatase, biomineralization associated |
affects expression multiple interactions |
ISO |
Hydroxychloroquine affects the expression of ALPL mRNA Hydroxychloroquine affects the reaction [Simvastatin affects the expression of ALPL mRNA] |
CTD |
PMID:28975700 |
|
NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases activity multiple interactions |
ISO |
Hydroxychloroquine results in increased activity of BAX protein bafilomycin A1 inhibits the reaction [Hydroxychloroquine results in increased activity of BAX protein] |
CTD |
PMID:12813466 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases cleavage increases activity |
ISO |
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [Hydroxychloroquine results in increased cleavage of CASP3 protein]; FAS protein affects the reaction [Hydroxychloroquine results in increased activity of CASP3 protein] |
CTD |
PMID:12813466 PMID:16734620 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of CCL2 mRNA |
CTD |
PMID:15139008 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Cd14 |
CD14 molecule |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CD14 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr18:28,335,522...28,337,383
Ensembl chr18:28,335,340...28,337,261
|
|
G |
Cd19 |
CD19 molecule |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CD19 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 1:180,987,286...180,993,920
Ensembl chr 1:180,987,286...180,993,975
|
|
G |
Cd27 |
CD27 molecule |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CD27 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 4:158,030,700...158,035,862
Ensembl chr 4:158,030,703...158,035,592
|
|
G |
Cd38 |
CD38 molecule |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CD38 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr14:67,172,062...67,212,328
Ensembl chr14:67,172,063...67,211,986
|
|
G |
Cd3d |
CD3 delta subunit of T-cell receptor complex |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CD3D mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 8:45,287,803...45,293,342
Ensembl chr 8:45,288,749...45,301,809
|
|
G |
Cd40lg |
CD40 ligand |
decreases expression |
ISO |
Hydroxychloroquine results in decreased expression of CD40LG protein |
CTD |
PMID:28793932 |
|
NCBI chr X:135,127,119...135,138,302
Ensembl chr X:135,126,969...135,138,306
|
|
G |
Cd74 |
CD74 molecule |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CD74 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases expression |
ISO |
Hydroxychloroquine results in decreased expression of CFLAR mRNA; Hydroxychloroquine results in decreased expression of CFLAR protein |
CTD |
PMID:16734620 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|
|
G |
Cldn1 |
claudin 1 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of CLDN1 mRNA |
CTD |
PMID:25752684 |
|
NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724
|
|
G |
Ctla4 |
cytotoxic T-lymphocyte-associated protein 4 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CTLA4 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963
|
|
G |
Ctsb |
cathepsin B |
affects localization multiple interactions |
ISO |
Hydroxychloroquine affects the localization of CTSB protein bafilomycin A1 inhibits the reaction [Hydroxychloroquine affects the localization of CTSB protein] |
CTD |
PMID:12813466 |
|
NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CXCL1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of CXCL10 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of CXCL1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr14:17,270,146...17,289,458
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases activity |
ISO |
Hydroxychloroquine inhibits the reaction [CYP2D6 protein results in increased metabolism of Metoprolol] Hydroxychloroquine results in decreased activity of CYP2D6 protein |
CTD |
PMID:10848718 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
affects expression multiple interactions |
ISO |
Hydroxychloroquine affects the expression of DHCR7 mRNA Hydroxychloroquine affects the reaction [Simvastatin affects the expression of DHCR7 mRNA] |
CTD |
PMID:28975700 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of ERN1 protein |
CTD |
PMID:25321315 |
|
NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
FAS protein affects the reaction [Hydroxychloroquine results in increased activity of CASP3 protein] |
CTD |
PMID:16734620 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression multiple interactions |
ISO |
Hydroxychloroquine affects the expression of HMGCR mRNA Simvastatin affects the reaction [Hydroxychloroquine affects the expression of HMGCR mRNA] |
CTD |
PMID:28975700 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Ifih1 |
interferon induced with helicase C domain 1 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of IFIH1 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 3:47,228,980...47,275,403
Ensembl chr 3:47,227,364...47,275,456
|
|
G |
Ifit3 |
interferon-induced protein with tetratricopeptide repeats 3 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of IFIT3 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:232,114,166...232,119,307
|
|
G |
Ifnb1 |
interferon beta 1 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of IFNB1 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 5:103,020,969...103,021,523
Ensembl chr 5:103,020,969...103,021,523
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Imiquimod] results in increased secretion of IL10 protein |
CTD |
PMID:31082466 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il10ra |
interleukin 10 receptor subunit alpha |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of IL10RA mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 8:45,563,009...45,578,041
Ensembl chr 8:45,563,137...45,578,061
|
|
G |
Il12b |
interleukin 12B |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of IL12B mRNA |
CTD |
PMID:25321315 |
|
NCBI chr10:28,888,832...28,903,796
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Hydroxychloroquine inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] Hydroxychloroquine inhibits the reaction [Fluorouracil results in increased secretion of IL1B protein] |
CTD |
PMID:16393772 PMID:32314717 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il23a |
interleukin 23 subunit alpha |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of IL23A mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
[Hydroxychloroquine co-treated with Imiquimod] results in increased secretion of IL6 protein; [Hydroxychloroquine co-treated with ODN2006] results in increased secretion of IL6 protein; Hydroxychloroquine inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein] Hydroxychloroquine results in increased expression of IL6 mRNA |
CTD |
PMID:9002011 PMID:25321315 PMID:31082466 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Irf3 |
interferon regulatory factor 3 |
increases expression multiple interactions increases phosphorylation |
ISO |
Hydroxychloroquine results in increased expression of IRF3 mRNA phenyl-N-tert-butylnitrone inhibits the reaction [Hydroxychloroquine results in increased phosphorylation of IRF3 protein] |
CTD |
PMID:25321315 |
|
NCBI chr 1:95,479,966...95,484,926
Ensembl chr 1:95,479,821...95,484,935
|
|
G |
Irf4 |
interferon regulatory factor 4 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of IRF4 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr17:33,721,800...33,742,570
Ensembl chr17:33,721,811...33,740,070
|
|
G |
Irf7 |
interferon regulatory factor 7 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of IRF7 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 1:196,367,380...196,370,943
Ensembl chr 1:196,367,361...196,370,832
|
|
G |
Itk |
IL2-inducible T-cell kinase |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of ITK mRNA |
CTD |
PMID:28863153 |
|
NCBI chr10:30,753,339...30,814,685
Ensembl chr10:30,753,344...30,814,685
|
|
G |
Jchain |
joining chain of multimeric IgA and IgM |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of JCHAIN mRNA |
CTD |
PMID:28863153 |
|
NCBI chr14:19,538,560...19,546,384
Ensembl chr14:19,538,952...19,546,298
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases phosphorylation multiple interactions |
ISO |
Hydroxychloroquine results in increased phosphorylation of JUN protein phenyl-N-tert-butylnitrone inhibits the reaction [Hydroxychloroquine results in increased phosphorylation of JUN protein] |
CTD |
PMID:25321315 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
[Hydroxychloroquine binds to and results in decreased activity of KCNH2 protein] which results in decreased export of Potassium; Hydroxychloroquine binds to and results in decreased activity of KCNH2 protein |
CTD |
PMID:34058295 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Lck |
LCK proto-oncogene, Src family tyrosine kinase |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of LCK mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 5:141,888,319...141,916,992
Ensembl chr 5:141,888,326...141,903,794
|
|
G |
Mavs |
mitochondrial antiviral signaling protein |
increases expression multiple interactions |
ISO |
Hydroxychloroquine results in increased expression of MAVS mRNA; Hydroxychloroquine results in increased expression of MAVS protein phenyl-N-tert-butylnitrone inhibits the reaction [Hydroxychloroquine results in increased expression of MAVS protein] |
CTD |
PMID:25321315 |
|
NCBI chr 3:118,451,650...118,466,094
Ensembl chr 3:118,451,743...118,466,094
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of MMP1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions decreases expression |
ISO |
Sirolimus inhibits the reaction [Hydroxychloroquine results in decreased expression of MMP2 protein] Hydroxychloroquine results in decreased expression of MMP2 mRNA; Hydroxychloroquine results in decreased expression of MMP2 protein |
CTD |
PMID:34278709 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Ms4a1 |
membrane spanning 4-domains A1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of MS4A1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 1:207,906,370...207,927,028
Ensembl chr 1:207,906,374...207,918,512
|
|
G |
Mvp |
major vault protein |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of MVP mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 1:181,594,734...181,622,336
Ensembl chr 1:181,594,734...181,622,380
|
|
G |
Nfatc1 |
nuclear factor of activated T-cells 1 |
affects expression |
ISO |
Hydroxychloroquine affects the expression of NFATC1 protein |
CTD |
PMID:28793932 |
|
NCBI chr18:74,046,421...74,156,041
Ensembl chr18:74,046,904...74,156,028
|
|
G |
Nfatc2 |
nuclear factor of activated T-cells 2 |
affects localization |
ISO |
Hydroxychloroquine affects the localization of NFATC2 protein |
CTD |
PMID:28793932 |
|
NCBI chr 3:157,195,970...157,328,640
Ensembl chr 3:157,198,872...157,328,325
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
increases degradation multiple interactions |
ISO |
Hydroxychloroquine results in increased degradation of NFKBIA protein phenyl-N-tert-butylnitrone inhibits the reaction [Hydroxychloroquine results in increased degradation of NFKBIA protein] |
CTD |
PMID:25321315 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Hydroxychloroquine inhibits the reaction [[IL1B protein results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitric Oxide] |
CTD |
PMID:16393772 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Ocln |
occludin |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of OCLN mRNA |
CTD |
PMID:25752684 |
|
NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
multiple interactions |
ISO |
Hydroxychloroquine binds to and results in decreased activity of PPT1 protein |
CTD |
PMID:30442709 |
|
NCBI chr 5:135,121,176...135,141,076
Ensembl chr 5:135,121,163...135,142,048
|
|
G |
Prdm1 |
PR/SET domain 1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of PRDM1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr20:47,959,858...47,981,488
Ensembl chr20:47,959,858...47,981,488
|
|
G |
Rasgrp1 |
RAS guanyl releasing protein 1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of RASGRP1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 3:104,168,549...104,230,107
Ensembl chr 3:104,170,013...104,230,056
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of RELA protein |
CTD |
PMID:25321315 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rig1 |
RNA sensor RIG-1 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of RIGI mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 5:55,321,229...55,369,947
Ensembl chr 5:55,321,235...55,370,819
|
|
G |
Rsad2 |
radical S-adenosyl methionine domain containing 2 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of RSAD2 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 6:43,046,514...43,059,737
Ensembl chr 6:43,047,658...43,059,699
|
|
G |
Sdc1 |
syndecan 1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of SDC1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr 6:31,562,799...31,585,267
Ensembl chr 6:31,562,739...31,585,264
|
|
G |
Serpine1 |
serpin family E member 1 |
multiple interactions |
ISO |
Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 mRNA]; Hydroxychloroquine inhibits the reaction [Poly I-C results in increased expression of SERPINE1 protein] |
CTD |
PMID:30341573 |
|
NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657
|
|
G |
Slamf7 |
SLAM family member 7 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of SLAMF7 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr13:84,135,656...84,154,528
Ensembl chr13:84,136,899...84,154,105
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions increases expression |
ISO |
Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of SQSTM1 protein]] [Dronabinol co-treated with Hydroxychloroquine] results in increased expression of SQSTM1 protein; [HU 211 co-treated with Hydroxychloroquine] results in increased expression of SQSTM1 protein Hydroxychloroquine results in increased expression of SQSTM1 protein |
CTD |
PMID:29426000 PMID:32773031 |
|
NCBI chr10:34,525,517...34,536,685
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Tlr7 |
toll-like receptor 7 |
decreases expression |
ISO |
Hydroxychloroquine results in decreased expression of TLR7 protein |
CTD |
PMID:22513098 |
|
NCBI chr X:27,027,380...27,054,309
Ensembl chr X:27,027,425...27,054,754
|
|
G |
Tlr9 |
toll-like receptor 9 |
multiple interactions decreases expression |
ISO |
Hydroxychloroquine inhibits the reaction [Fluorouracil results in increased secretion of TLR9 protein] Hydroxychloroquine results in decreased expression of TLR9 protein |
CTD |
PMID:22513098 PMID:32314717 |
|
NCBI chr 8:106,864,680...106,868,796
Ensembl chr 8:106,864,680...106,868,796
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Hydroxychloroquine results in increased expression of TNF mRNA [Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of TNF mRNA; Hydroxychloroquine inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein] |
CTD |
PMID:9002011 PMID:25321315 PMID:28863153 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf17 |
TNF receptor superfamily member 17 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of TNFRSF17 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr10:4,301,023...4,306,889
Ensembl chr10:4,301,038...4,306,788
|
|
G |
Traf3 |
Tnf receptor-associated factor 3 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of TRAF3 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 6:130,199,696...130,307,168
Ensembl chr 6:130,206,484...130,305,481
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of TRAF6 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trim21 |
tripartite motif-containing 21 |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of TRIM21 mRNA |
CTD |
PMID:25321315 |
|
NCBI chr 1:156,964,896...156,987,504
Ensembl chr 1:156,964,913...156,987,440
|
|
G |
Txnip |
thioredoxin interacting protein |
multiple interactions |
ISO |
Hydroxychloroquine inhibits the reaction [Metformin inhibits the reaction [Galactose results in increased expression of TXNIP protein]] |
CTD |
PMID:29426000 |
|
NCBI chr 2:184,093,079...184,096,882
Ensembl chr 2:184,092,991...184,096,886
|
|
G |
Uxt |
ubiquitously-expressed, prefoldin-like chaperone |
increases expression |
ISO |
Hydroxychloroquine results in increased expression of UXT mRNA |
CTD |
PMID:25321315 |
|
NCBI chr X:1,126,110...1,138,670
Ensembl chr X:1,126,162...1,138,663
|
|
G |
Vcl |
vinculin |
multiple interactions |
ISO |
Hydroxychloroquine inhibits the reaction [[Dexamethasone co-treated with beta-glycerophosphoric acid] results in increased expression of VCL protein] |
CTD |
PMID:28975700 |
|
NCBI chr15:3,265,776...3,355,586
Ensembl chr15:3,265,815...3,355,606
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
[Hydroxychloroquine co-treated with Methotrexate co-treated with Sulfasalazine] results in decreased expression of XBP1 mRNA |
CTD |
PMID:28863153 |
|
NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1 protein |
CTD |
PMID:23466342 PMID:27888070 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
decreases expression multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCB1B protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[NFKB1 protein binds to RELA protein] which results in increased expression of ABCB1B mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Curcumin results in decreased expression of ABCB1B protein] |
CTD |
PMID:18006147 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
decreases expression |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC1 protein |
CTD |
PMID:27888070 |
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [erucin results in increased expression of ABCC2 mRNA] |
CTD |
PMID:15896333 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of ABCC5 protein |
CTD |
PMID:23994249 |
|
NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ERBB2 results in increased expression of ABCG2 protein] |
CTD |
PMID:21712253 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Abl1 |
ABL proto-oncogene 1, non-receptor tyrosine kinase |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased chemical synthesis of Histamine]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[BCR protein mutant form binds to ABL1 protein mutant form] which results in increased expression of HDC mRNA] |
CTD |
PMID:16849647 |
|
NCBI chr 3:14,979,853...15,083,065
Ensembl chr 3:14,979,853...15,083,065
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel monoxide analog results in increased expression of ACTA2 protein] |
CTD |
PMID:33895847 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Acvr2b |
activin A receptor type 2B |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of ACVR2B mRNA] |
CTD |
PMID:12710931 |
|
NCBI chr 8:119,138,901...119,178,477
Ensembl chr 8:119,138,812...119,170,458
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Carbon Monoxide results in increased expression of ADIPOQ protein] which results in increased phosphorylation of NOS3 protein] |
CTD |
PMID:19356108 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adra1a |
adrenoceptor alpha 1A |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[cirazoline results in increased activity of ADRA1A protein] which results in increased transport of Glucose] |
CTD |
PMID:15550506 |
|
NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Vitamin A results in increased expression of AGER protein] |
CTD |
PMID:21807062 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [AGT protein results in increased expression of POSTN mRNA] |
CTD |
PMID:15121739 PMID:16325820 PMID:23300732 PMID:25398788 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
increases expression decreases expression multiple interactions |
EXP ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR mRNA; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in increased expression of AHR protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AHR mRNA 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [TGFB1 protein results in increased activity of AHR protein] |
CTD |
PMID:22406437 PMID:27020609 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased expression of AKR1B1 mRNA] |
CTD |
PMID:17640564 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akr1b10 |
aldo-keto reductase family 1 member B10 |
decreases expression |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one results in decreased expression of AKR1B10 protein |
CTD |
PMID:23994249 |
|
NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852
|
|
G |
Akr1c3 |
aldo-keto reductase family 1, member C3 |
multiple interactions |
ISO |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cadmium acetate results in increased expression of AKR1C3 protein] |
CTD |
PMID:21787718 |
|
NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases reaction decreases expression decreases phosphorylation increases expression decreases activity |
ISO EXP |
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the localization of [PDK1 protein binds to AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one affects the reaction [1-Methyl-4-phenylpyridinium affects the expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one analog results in decreased expression of and results in decreased phosphorylation of AKT1 protein; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [(4-(((2-(3-fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [1,3-dichloro-2-propanol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [2,3',4,4',5-pentachlorobiphenyl results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [27-hydroxycholesterol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [4-hydroxyestradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein] which results in decreased degradation of NOS3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Clioquinol co-treated with Copper] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[FGF7 protein results in increased phosphorylation of AKT1 protein] which results in increased expression of ESR1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Gallic Acid co-treated with gallocatechol co-treated with epigallocatechin gallate co-treated with epicatechin gallate] inhibits the reaction [Hydrogen Peroxide results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[HSPA1A protein co-treated with Formaldehyde] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[MIR21 mRNA results in decreased susceptibility to Cisplatin] which results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [[Rosiglitazone co-treated with IAPP protein] results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Acetylcysteine results in increased activity of and results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [arsenite results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Atrazine results in decreased expression of and results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [BDNF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [bisphenol A results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Caffeine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Camptothecin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Capsaicin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cholesterol, HDL results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Copper Sulfate results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Cotinine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Curcumin results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [cyanoginosin LR results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [DEFA2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Diethylhexyl Phthalate results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dronabinol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Endosulfan results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Estradiol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Ethanol results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [FGF2 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Furazolidone results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [gadodiamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [hemistepsin results in decreased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [INS protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [KMUP 1 results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [methanandamide results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel chloride results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [nickel monoxide analog results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nicotine results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Nifedipine promotes the reaction [[Hydrogen Peroxide co-treated with Simvastatin] results in increased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased expression of AKT1 mRNA]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NLRC5 protein results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxygen deficiency results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Paclitaxel results in increased activity of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Particulate Matter results in increased phosphorylation of AKT1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [PDGFB prot |